Publikationen
Unsere Forschungsergebnisse bringen wir aktiv in die Fachwelt ein.
Publikationen
Wir publizieren aktuelle wissenschaftliche Erkenntnisse in renommierten Fachzeitschriften und präsentieren sie auf nationalen wie internationalen Konferenzen. So gestalten wir die klinische Krebsforschung mit und fördern den wissenschaftlichen Dialog auf höchstem Niveau.
Veröffentlichungsrate von über 95%
Das Swiss Cancer Institute hat eine sehr hohe Veröffentlichungsrate von über 95%. In einem 2023 erschienen Artikel wurde untersucht, wie oft unsere Studien veröffentlicht wurden, es wurden 240 Studien einbezogen, die zwischen 1986 und 2021 die Patientenrekrutierung abgeschlossen haben.
216 von 240 Studien (90%) wurden Fachzeitschriften mit Peer-Review veröffentlicht, 14 wurden in anderen Formaten publiziert, was eine Gesamtveröffentlichungsrate von 96% ergibt.
Bei Studien, die früher abgeschlossen wurden, war die Wahrscheinlichkeit einer Veröffentlichung geringer. Doch selbst bei diesen Studien lag die Veröffentlichungsrate bei etwa 80%, was deutlich höher ist als in der Literatur angegeben.
Hayoz S, Kasenda B, Schenker AL, et al. Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK). BMJ Open 2023;0:e068490. doi:10.1136/
Fakten & Zahlen
Im Jahr 2024 erschienen 38 Artikel mit Bezug zum Swiss Cancer Institute (ehemals SAKK) in verschiedenen wissenschaftlichen Fachzeitschriften. Die Anzahl der Artikel ist vergleichbar mit den Vorjahren. Das Swiss Cancer Institute war unter dem früheren Nahmen "SAKK" mit 18 Postern und 23 Vorträgen auf den wichtigsten Onkologiekongressen sowie auf lokalen Veranstaltungen gut vertreten.
Ein besonderes Highlight war die mündliche Präsentation der SAKK 41/13 Aspirin-Studie auf dem Kongress der European Society for Medical Oncology (ESMO) in Barcelona. Diese randomisierte, placebokontrollierte Phase-III-Studie untersuchte den Einsatz einer adjuvanten Aspirinbehandlung bei Patienten mit PIK3CA-mutiertem Darmkrebs.
Eine Übersichtstabelle mit der Anzahl der Manuskripte und Konferenzpräsentationen im Vergleich zu den Vorjahren finden Sie im Jahresbericht.
-
Stefanie Hayoz
Head of Statistics
Publikationsliste
Alle Manuskripte mit Swiss Cancer Institute Beteiligung seit 2015 sind in folgender Übersicht zu finden:
Publikationen
Typ
Journal
Jahr
Krankheitsgruppe
Studie
Title
Autoren
Impact-Faktor
Typ
Swiss Cancer Institute trialsJournal
RADIOTHER ONCOLJahr
2025Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Long-term urinary continence and influencing factors after salvage radiotherapy: Results of the SAKK 0910 dose escalation trialAutoren
Schröder C, Zwahlen DR, Schär S, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Beck M, Riesterer O, Thalmann GN, Aebersold DM, Ghadjar PImpact-Faktor
4.9Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2025Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 TrialsAutoren
Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schär C, Berlin AM, Zwahlen DR, Simko JP, Hölscher T, Efstathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SGImpact-Faktor
56.7Typ
Swiss Cancer Institute trialsJournal
EXP HEMATOL ONCOLJahr
2025Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 11/16Title
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after = 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trialAutoren
Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach NImpact-Faktor
13.5Typ
Swiss Cancer Institute trialsJournal
JTO CLIN RES REPJahr
2025Krankheitsgruppe
Lung CancersStudie
SAKK 16/XX not operatedTitle
Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.Autoren
Raimann S, Schär S, Hayoz S, Guckenberger M, Finazzi T, Opitz I, Schmid S, Mark M, Addeo A, Mauti LA, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König DImpact-Faktor
3.0Typ
Swiss Cancer Institute trialsJournal
CLIN BREAST CANCERJahr
2025Krankheitsgruppe
Breast CancersStudie
SAKK 21/12Title
Final overall survival analysis of the phase II SAKK 21/12 trial of transdermal CR1447 in patients with metastatic breast cancerAutoren
Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann BImpact-Faktor
2.7Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2025Krankheitsgruppe
Breast CancersStudie
SAKK 23/16Title
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Autoren
Knauer M, Egle D, Hayoz S, Sávolt Á, Tausch C, Bucher S, Simonson C, Satler R, Heil J, Bekes I, Bjelic-Radisic V, Audeh W, Lam GT, Menicucci A, Muenst S, Ostapenko V, Kurzeder C, Heidinger M, Weber WPImpact-Faktor
7.5Typ
Swiss Cancer Institute trialsJournal
BLOODJahr
2025Krankheitsgruppe
LeukemiasStudie
SAKK 34/17Title
Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17Autoren
Condoluci A, Romano I, Dietrich D, Pini K, Stüssi G, Müller G, Cantoni N, Cathomas R, Mey U, Widmer A, Zenz T, Gregor M, Heim D, Andres M, Benz R, Rossi DImpact-Faktor
21.0Typ
Swiss Cancer Institute trialsJournal
BLOOD ADVJahr
2025Krankheitsgruppe
LymphomasStudie
SAKK 35/10Title
Rituximab-Lenalidomide as frontline therapy in Follicular Lymphoma Patients: a 10-year Update of the SAKK 35/10 Randomized TrialAutoren
Kimby EK Professor Emerita, Schär S, Pirosa MC, Vanazzi A, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJMJ, Krasniqi F, Voegeli M, Novak U, Zander T, Bersvendsen H, Mamot C, Mingrone W, Stathis A, Dirnhofer S, Hayoz S, Østenstad B, Zucca EImpact-Faktor
7.4Typ
Swiss Cancer Institute trialsJournal
CLIN CANCER RESJahr
2025Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 41/13Title
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 TrialAutoren
Güller U, Hayoz S, Horber D, Jochum W, De Dosso S, Koeberle D, Schacher S, Inauen R, Stahl M, Delaunoit T, Ettrich T, Bodoky G, Michel P, Koessler T, Rothgiesser K, Calmonte S, Joerger MImpact-Faktor
10.4Typ
Swiss Cancer Institute servicesJournal
SWISS MED WKLYJahr
2025Krankheitsgruppe
-Studie
-Title
Blastic plasmacytoid dendritic cell neoplasm: A Swiss case series of a very rare disease and a structured review of the literatureAutoren
Meier-Lienhard R, Suter C, Pabst T, Hitz F, Passweg JR, Spertini O, Cantoni N, Betticher D, Simeon L, Medinger M, Hayoz S, Schmidt AImpact-Faktor
4.2Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2025Krankheitsgruppe
Lung CancersStudie
ETOP BEAT-mesoTitle
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trialAutoren
Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, Shah R, de Marinis F, Cove Smith L, Bernabé R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Nadal E, Vila Martinez L, Talbot T, Roschitzki-Voser H, Dimopoulou G, Schär S, Ruepp B, Savic S, Peters S, Stahel RImpact-Faktor
56.7Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2025Krankheitsgruppe
LymphomasStudie
HD 21Title
Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, ingle-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 TrialAutoren
Ferdinandus J, Kaul H, Fosså A, Hüttmann A, Keil F, Ko YD, Hitz F, Schwarz M, Trenker C, Kerkhoff A, Staib P, Wille K, Dresel I, Hahn D, Hertenstein B, Moosmann P, Mey U, Balabanov S, Armytage T, Roncolato F, Hellmuth JC, Hertzberg M, Kobe C, Klapper W, Baues C, Eich HT, Kreissl S, Fuchs M, Jablonski J, Schneider G, Tharmaseelan H, Eichenauer DA, von Tresckow B, Borchmann P, Bröckelmann PJImpact-Faktor
42.1Typ
Collaborative group trialsJournal
HAEMATOLOGICAJahr
2025Krankheitsgruppe
LeukemiasStudie
HOVON 132Title
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsAutoren
Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevicius L, Juliusson G, Van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, Ossenkoppele GJ, De Leeuw DC, Cloos JImpact-Faktor
8.2Typ
Collaborative group trialsJournal
BLOOD ADVJahr
2025Krankheitsgruppe
LeukemiasStudie
HOVON 42, HOVON 42A, HOVON 43, HOVON 81, HOVON 92, HOVON 102, HOVON 103, HOVON 132Title
An Improved Prognostic Model for Patients with Acute Myeloid Leukemia and First RelapseAutoren
van der Maas NG, Breems D, Klerk CPW, Pabst T, Gradowska P, Thomas A, Biemond BJ, Kuball J, Van Elssen CHMJ, Visser O, Vekemans MC, Graux C, Maertens J, Knapper S, Dennis M, Freeman S, Thomas I, Beverloo HB, Huls G, Craddock C, Valk PJM, Vyas P, Russell N, Ossenkoppele G, Löwenberg B, Cornelissen JJ, Versluis JImpact-Faktor
7.4Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2025Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolAutoren
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NWImpact-Faktor
35.9Typ
Swiss Cancer Institute trialsJournal
BJU INTJahr
2024Krankheitsgruppe
Urogenital CancersStudie
SAKK 06/17Title
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabineAutoren
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas RImpact-Faktor
3.7Typ
Swiss Cancer Institute trialsJournal
CLIN TRANSL RADIAT ONCOLJahr
2024Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trialAutoren
Zwahlen DR, Schröder C, Holer L, Bernhard J, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Martin Putora P, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Giovanni Bosetti D, Reuter C, Gomez S, Khanfir K, Beck M, Thalmann GN, Aebersold DM, Ghadjar PImpact-Faktor
3.1Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2024Krankheitsgruppe
Lung CancersStudie
SAKK 19/17Title
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Autoren
Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi R, Fischer Maranta A, Bastian S, von Moos R, Joerger M, Früh MImpact-Faktor
7.6Typ
Swiss Cancer Institute trialsJournal
SURG ONCOLJahr
2024Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 40/00Title
Is surgical quality more important than radicality? Long-term outcomes of stage I–III colon cancer (SAKK 40/00)Autoren
Maurer CA, Dietrich D, Schilling MK, Brauchli P, Kessler K, Käser SAImpact-Faktor
2.3Typ
Swiss Cancer Institute trialsJournal
CLIN COLORECTAL CANCJahr
2024Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 41/16Title
Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: a multicenter phase Ib trial (RECAP)–SAKK 41/16Autoren
Bastian S, Joerger M, Holer L, Bärtschi D, Guckenberger M, Jochum W, Koeberle D, Siebenhüner AR, Wicki A, Berger MD, Winterhalder RC, Largiadèr CR, Löffler M, Mosna-Firlejczyk K, Maranta AF, Pestalozzi BC, Csajka C, von Moos RImpact-Faktor
3.3Typ
Swiss Cancer Institute trialsJournal
CANCER CHEMO PHARMACOLJahr
2024Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 65/16Title
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I dose escalation trial (SAKK 65/16)Autoren
Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Sessa C, Stathis A, Halbherr S, Huisinga W, Joerger M, Kloft CImpact-Faktor
2.7Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2024Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 65/16Title
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)Autoren
Colombo I, Koster K, Holer L, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Joerger MImpact-Faktor
8.4Typ
Swiss Cancer Institute trialsJournal
BONE REPJahr
2024Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 80/19_AlpineTIRTitle
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA studyAutoren
Mark M, Mora AR, Winder T, Stathis A, Jakob A, Müller G, Hayoz S, Reimann P, Petrausch U, von Moos RImpact-Faktor
4.3Typ
Swiss Cancer Institute servicesJournal
CLIN TRANSL RADIAT ONCOLJahr
2024Krankheitsgruppe
Radio-OncologyStudie
-Title
Deep inspirational breast hold (DIBH) for right breast irradiation: Improved sparing of liver and lung tissueAutoren
Mader T, Pace R, Boucas da Silva RT, Erwin Johannes Adam L, Näf G, Charles Winter C, Maria Aspradakis M, Radovic M, Spyridonidis A, Hayoz S, Gertrud Baumert BImpact-Faktor
2.7Typ
Swiss Cancer Institute servicesJournal
JITJahr
2024Krankheitsgruppe
MelanomasStudie
-Title
Effects of CTLA-4 Single Nucleotide Polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanomaAutoren
de Joode K, Rojas Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin H, von Moos R, Joerger M, Levesque MP, Aeppli S, Mangana J, Mangas C, Meyer S, Leoni-Parvex S, Mathijssen R, Metaxas YImpact-Faktor
3.9Typ
Swiss Cancer Institute servicesJournal
CAN UROL ASSOC JJahr
2024Krankheitsgruppe
Urogenital CancersStudie
-Title
Efficacy and tolerability of Bacillus Calmette-Guérin Strain Russia for the treatment of non-muscle-invasive bladder cancer – analysis of a prospective registryAutoren
Flury-Sutter S, Heuzeroth F, Arbelaez E, Bubendorf L, Püschel H, Hayoz S, Rentsch CAImpact-Faktor
1.9Typ
Swiss Cancer Institute servicesJournal
J THORAC ONCOL CLIN RES REPJahr
2024Krankheitsgruppe
Lung CancersStudie
-Title
First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world studyAutoren
Moliner L, Zellweger N, Schmid S, Bertschinger M, Waibel C, Cerciello F, Froesch P, Mark M, Bettini A, Häuptle P, Blum V, Holer L, Hayoz S, Früh MImpact-Faktor
3.0Typ
Swiss Cancer Institute servicesJournal
J CANCER RES CLIN ONCOLJahr
2024Krankheitsgruppe
Urogenital CancersStudie
-Title
Metronomic Cyclophosphamide for Bone Marrow Carcinomatosis in Metastatic Castration-resistant Prostate CancerAutoren
Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt CImpact-Faktor
2.7Typ
Swiss Cancer Institute servicesJournal
EUR UROL FOCUSJahr
2024Krankheitsgruppe
Urogenital CancersStudie
-Title
Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING)Autoren
Wetterauer C, Matthias M, Pueschel H, Deckart A, Bubendorf L, Mortezavi A, Arbelaez E, Jean Winkel D, Heye T, Boll DT, Merkle E, Hayoz S, Seifert HH, Rentsch CAImpact-Faktor
4.9Typ
Swiss Cancer Institute servicesJournal
SUPPORT CARE CANCERJahr
2024Krankheitsgruppe
-Studie
-Title
Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single centre study with intrapatient comparisonAutoren
Johnson K, Stoffel B, Schwitter M, Hayoz S, Rojas Mora A, Fischer A, El Saadany T, Hasler U, von Moos R, Patzen A, Mark M, Roberts G, Cathomas RImpact-Faktor
2.8Typ
Swiss Cancer Institute servicesJournal
JTO CLIN RES REPJahr
2024Krankheitsgruppe
Lung CancersStudie
-Title
Real-world outcomes of patients with malignant pleural mesothelioma receiving combination ipilimumab and nivolumab as first- or later line treatmentAutoren
Schmid S, Holer L, Gysel K, Koster K, Rothschild S, Boos L, Frehner L, Cardoso S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Von der Mühll-Schill C, Frueh M, Maut LAImpact-Faktor
3.0Typ
OtherJournal
SWISS MED WKLYJahr
2024Krankheitsgruppe
Imaging in Diagnostic and Therapy Monitoring (IDaTM)Studie
-Title
Advancements in lung cancer: a comprehensive perspective on diagnosis, staging, therapy and follow-up from the SAKK Working Group on Imaging in Diagnosis and Therapy MonitoringAutoren
Jungblut L, Rizzo SM, Ebner L, Kobe A, Nguyen-Kim TDL, Martini K, Roos J, Puligheddu C, Afshar-Oromieh A, Christe A, Dorn P, Funke-Chambour M, Hötker A, Frauenfelder TImpact-Faktor
4.2Typ
OtherJournal
PLOS ONEJahr
2024Krankheitsgruppe
Network for Outcomes ResearchStudie
-Title
Cost-Effectiveness & Budget Impact Analysis of Olaparib for BRCA 1/2 Germline-mutated Pancreatic CancerAutoren
Mehra T, Lupatsch JE, Kössler T, Dedes K, Siebenhüner AR, von Moos R, Wicki A, Schwenkglenks MEImpact-Faktor
2.9Typ
OtherJournal
CANCER TREAT REVJahr
2024Krankheitsgruppe
-Studie
-Title
The active involvement of patients in oncology researchAutoren
Ganz-Blaettler U, Liptrott SJ, Tolotti A, Cefalì M, Aeschlimann C, Vilei SB, Colombo I, Hatziandreou E, Kosmidis T, Linardou H, Pfau R, Sgourou S, Sessa CImpact-Faktor
9.6Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2024Krankheitsgruppe
LeukemiasStudie
CLL13Title
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialAutoren
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst BImpact-Faktor
41.6Typ
Collaborative group trialsJournal
HAEMATOLOGICAJahr
2024Krankheitsgruppe
LeukemiasStudie
EBMT HCT vs CTTitle
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III studyAutoren
Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, Cornelissen JImpact-Faktor
8.2Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2024Krankheitsgruppe
Gynecological CancersStudie
ENGOT-en7_AtTEndTitle
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialAutoren
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MPImpact-Faktor
41.6Typ
Collaborative group trialsJournal
CLIN CANCER RESJahr
2024Krankheitsgruppe
Lung CancersStudie
ETOP BOOSTERTitle
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER TrialAutoren
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RAImpact-Faktor
10.4Typ
Collaborative group trialsJournal
BLOODJahr
2024Krankheitsgruppe
LeukemiasStudie
GRAALL 2003, GRAALL 2005Title
NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patientsAutoren
Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Rigal-Huguet F, Ducassou S, Lheritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre EA, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi VImpact-Faktor
20.3Typ
Collaborative group trialsJournal
LANCETJahr
2024Krankheitsgruppe
LymphomasStudie
HD 21Title
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialAutoren
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl VImpact-Faktor
98.4Typ
Collaborative group trialsJournal
CELL DEATH DISJahr
2024Krankheitsgruppe
LeukemiasStudie
HOVON 102Title
High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)Autoren
Bajrami Saipi M, Ruiba A, Schittenhelm MM, Blumenstock G, Gyorffy B, Fazio S, Hafner M, Ahrens AL, Aldinger L, Aellig V, Kavelaars FG, Nombela-Arrieta C, Fend F, Valk PJM, Christoph D, Kampa-Schittenhelm KMImpact-Faktor
8.1Typ
Collaborative group trialsJournal
CANCER REPJahr
2024Krankheitsgruppe
LymphomasStudie
HOVON 127/ SAKK 37/16Title
Effectiveness of fractionated rituximab in preventing tumorlysis syndrome in aggressive B-cell lymphoma: Insights fromreal-life clinical practiceAutoren
Mohamad J, Bouroumeau A, McKee TA, Mach N, Samii K, Chamuleau M, Stenner F, Tamburini J, Lang NImpact-Faktor
1.5Typ
Collaborative group trialsJournal
BLOOD CANCER JJahr
2024Krankheitsgruppe
LeukemiasStudie
HOVON 132Title
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trialAutoren
van der Maas NG, Versluis J, Nasserinejad K, van Rosmalen J, Pabst T, Maertens J, Breems D, Manz M, Cloos J, Ossenkoppele GJ, Floisand Y, Gradowska P, Löwenberg B, Huls G, Postmus D, Pignatti F, Cornelissen JJImpact-Faktor
12.9Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2024Krankheitsgruppe
LeukemiasStudie
HOVON 81, HOVON 103, HOVON 102, HOVON 132Title
Risk Stratification in Older Intensively Treated Patients With AMLAutoren
Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, Kennedy A, Moore R, Boertjes E, Vonk CM, Kavelaars FG, Rijken M, Gilkes A, Schwab C, Beverloo HB, Manz M, Visser O, Van Elssen CHMJ, de Weerdt O, Tick LW, Biemond BJ, Vekemans MC, Freeman SD, Harrison CJ, Cook JA, Dennis M, Knapper S, Thomas I, Craddock C, Ossenkoppele GJ, Löwenberg B, Russell N, Valk PJM, Vyas PImpact-Faktor
42.1Typ
Collaborative group trialsJournal
EUR J CANCERJahr
2024Krankheitsgruppe
Breast CancersStudie
IBCSG 22-00Title
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00Autoren
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano GImpact-Faktor
7.6Typ
Collaborative group trialsJournal
JAMA ONCOLJahr
2024Krankheitsgruppe
Breast CancersStudie
IBCSG 24-02Title
Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT TrialAutoren
O’Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell’Orto P, Láng I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, MüllerB, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MMImpact-Faktor
22.3Typ
Collaborative group trialsJournal
ESMO OPENJahr
2024Krankheitsgruppe
Breast CancersStudie
IBCSG 36-07Title
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancerAutoren
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia AImpact-Faktor
7.1Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2024Krankheitsgruppe
Breast CancersStudie
IBCSG 48-14 POSITIVETitle
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt PregnancyAutoren
Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A , Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Eon Lee J, Walshe JM, Ruiz-Borrego M, Moore HC, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Tanja Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FAImpact-Faktor
42.1Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2024Krankheitsgruppe
Breast CancersStudie
IBCSG 50-14 OLYMPIATitle
Patient-reported outcomes in OlympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in g BRCA1/2 mutations and high-risk human epidermial growth factor receptor 2-negative early breast cancerAutoren
Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas E-M, Armstrong A, Im S-A, Song C-G, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, FrauchigerHeuer H, Wimberger P, t’Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Seok Lee L, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer Jr CE, Tutt ANJImpact-Faktor
42.1Typ
Collaborative group trialsJournal
LANCETJahr
2024Krankheitsgruppe
LymphomasStudie
TRIANGLETitle
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkAutoren
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster EImpact-Faktor
98.4Typ
Swiss Cancer Institute trialsJournal
J CLIN ONCOLJahr
2023Krankheitsgruppe
Urogenital CancersStudie
SAKK 06/17Title
Perioperative chemo-immunotherapy with Durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single arm phase II trial SAKK 06/17Autoren
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch UImpact-Faktor
45.3Typ
Swiss Cancer Institute trialsJournal
BMJ OPENJahr
2023Krankheitsgruppe
Urogenital CancersStudie
SAKK 06/19Title
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single arm phase 2 trial (SAKK 06/19)Autoren
Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas RImpact-Faktor
3.007Typ
Swiss Cancer Institute trialsJournal
J CLIN ONCOLJahr
2023Krankheitsgruppe
Urogenital CancersStudie
SAKK 08/16Title
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Autoren
Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance JI, González-Del-Alba A, Delgado MT, Nole F, Turco F, Pereira Mestre R, Ribi K, Cathomas RImpact-Faktor
45.3Typ
Swiss Cancer Institute trialsJournal
ESMO OPENJahr
2023Krankheitsgruppe
Lung CancersStudie
SAKK 16/96, SAKK 16/00, SAKK 16/01, SAKK 16/08Title
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small cell lung cancer. Retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01 and 16/14Autoren
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Opitz I, Guckenberger M, Früh M, Betticher DC, Ris HB, Stupp R, Rothschild SI, Bubendorf L, Pless MImpact-Faktor
7.3Typ
OtherJournal
JAMA ONCOLJahr
2023Krankheitsgruppe
Breast CancersStudie
SAKK 22/10Title
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialAutoren
Huober J, Thürlimann B, Dietrich DImpact-Faktor
33.01Typ
Swiss Cancer Institute trialsJournal
JAMA SURGJahr
2023Krankheitsgruppe
Breast CancersStudie
SAKK 23/16Title
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast CancerAutoren
Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zimmermann F, Montagna G, Fitzal F, Gnant M, Ruhstaller T, Muenst S, Mueller A, Lelièvre L, Heil J, Knauer M, Egle D, Sávolt Á, Heidinger M, Kurzeder C; TAXIS Study Writing Group; Zwahlen DR, Gruber G, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Smanykó V, Vrieling C, Satler R, Hagen D, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer CF, Loibl S, Winkler J, Lam GT, Fehr MK, Kohlik M, Clerc K, Ostapenko V, Maggi N, Schulz A, Andreozzi M, Goldschmidt M, Saccilotto R, Markellou P.Impact-Faktor
16.681Typ
Swiss Cancer Institute trialsJournal
ANN SURG ONCOLJahr
2023Krankheitsgruppe
Breast CancersStudie
SAKK 23/16Title
Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: Prospective study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Autoren
Weber WP, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz A, Mueller A, Ackerknecht M, Tampaki EC, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanykó V, Hagen D, Müller DJ, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer MImpact-Faktor
5.344Typ
Swiss Cancer Institute trialsJournal
BREAST CANCER RES TRJahr
2023Krankheitsgruppe
Breast CancersStudie
SAKK 23/16Title
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: Prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Autoren
Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz A, Maggi N, Saccilotto R, Heidinger M, Mueller A, Tampaki EC, Bjelic-Radisic V, Sávolt Á, Smanykó V, Hagen D, Müller DJ, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kuemmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer CF, Montagna G, Reitsamer R, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber WPImpact-Faktor
4.845Typ
Swiss Cancer Institute trialsJournal
SCI REPJahr
2023Krankheitsgruppe
Breast CancersStudie
SAKK 24/14Title
Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative, EGFR positive breast cancer A multicenter single arm phase II trial [SAKK 24/14]Autoren
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer U, Caspar C, Deuster S, Senn M, Winterhalder R, Rochlitz CImpact-Faktor
4.996Typ
Swiss Cancer Institute trialsJournal
eClinicalMedicineJahr
2023Krankheitsgruppe
LymphomasStudie
SAKK 36/13Title
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Autoren
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner CImpact-Faktor
15.1Typ
Swiss Cancer Institute trialsJournal
LEUKEMIAJahr
2023Krankheitsgruppe
LymphomasStudie
SAKK 39/16Title
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trialAutoren
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen CImpact-Faktor
12.883Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2023Krankheitsgruppe
SarcomasStudie
SAKK 57/16Title
SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with >2y median follow upAutoren
Digklia A, Kollár A, Dietrich D, Kronig MN, Britschgi C, Rordorf T, Joerger M, F. Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt CImpact-Faktor
5.417Typ
Swiss Cancer Institute servicesJournal
SWISS MED WKLYJahr
2023Krankheitsgruppe
-Studie
-Title
A long-term retrospective observational study at a medium-sized medical oncology service in Switzerland: comparison of overall survival with a national cohort and adherence to treatment guidelinesAutoren
Gross-Erne M, Zimmerli L, Bassetti S, Li Q, Feller A, Mingrone WImpact-Faktor
2.1Typ
Swiss Cancer Institute servicesJournal
LUNG CANCERJahr
2023Krankheitsgruppe
Lung CancersStudie
-Title
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC): A Swiss cohort studyAutoren
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark MT, Rothschild SI, Addeo A, Janthur WD, Siano M, Boos L, Britschgi C, Früh MImpact-Faktor
5.3Typ
Swiss Cancer Institute servicesJournal
INVEST NEW DRUGSJahr
2023Krankheitsgruppe
Developmental TherapeuticsStudie
BASILEA CDI-CS-002Title
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a studyAutoren
Joerger M, Hundsberger T, Haefliger S, von Moos R, Hottinger AF, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis AImpact-Faktor
3.4Typ
MethodologyJournal
BMJ OPENJahr
2023Krankheitsgruppe
-Studie
-Title
Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)Autoren
Hayoz S, Kasenda B, Schenker AL, Kopp C, Schär S, Thürlimann B, von Moos R, Pless MImpact-Faktor
3.007Typ
Collaborative group trialsJournal
NEW ENGL J MEDJahr
2023Krankheitsgruppe
LeukemiasStudie
CLL13Title
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaAutoren
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek MImpact-Faktor
59.558Typ
Collaborative group trialsJournal
BLOODJahr
2023Krankheitsgruppe
LeukemiasStudie
CLL13Title
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsAutoren
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater APImpact-Faktor
10.452Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2023Krankheitsgruppe
Gastrointestinal CancersStudie
DANTETitle
Perioperative atezolizumab in combination with FLOT chemotherapy vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the phase II portion of DANTE, a randomized, multicenter, phase II/III trial of the FLOT-AIO German Gastric Cancer Study Group and Swiss Group for Clinical Cancer Research SAKKAutoren
Lorenzen S, Götze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, Lindig U, Heuer V, Kretzschmar A, Goekkurt E, Haag GM, Riera-Knorrenschild J, Bolling C, Hofheinz RD, Zhan T, Angermeier S, Ettrich TJ, Siebenhuener AR, Elshafei M, Bechstein WO, Gaiser T, Loose M, Sookthai D, Kopp C, Pauligk C, Al-Batran SEImpact-Faktor
45.3Typ
Collaborative group trialsJournal
CANCERSJahr
2023Krankheitsgruppe
SarcomasStudie
GISG 11, PazoQoLTitle
Electronic Patient Reported Outcome (ePRO) Measures in Patients with Soft Tissue Sarcoma (STS) Receiving Palliative 3 TreatmentAutoren
Hofer, S., Hentschel, L.,Richter, S., Blum, V., Kramer, M., Kasper, B., Riese, C., Schuler, M.KImpact-Faktor
6.639Typ
Collaborative group trialsJournal
BLOODJahr
2023Krankheitsgruppe
LeukemiasStudie
GRAALL 2003, GRAALL 2005, GRAALL 2014Title
Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL studyAutoren
Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, Passet M, Grardel N, Delabesse E, Kubetzko S, Caye-Eude A, Meyer C, Marschalek R, Lafage-Pochitaloff M, Thiebaut-Bertrand A, Balsat M, Escoffre-Barbe M, Blum S, Baumann M, Banos A, Straetmans N, Gallego-Hernanz MP, Chalandon Y, Graux C, Soulier J, Leguay T, Hunault M, Huguet F, Lhéritier V, Dombret H, Boissel N, Clappier EImpact-Faktor
10.452Typ
Collaborative group trialsJournal
BLOODJahr
2023Krankheitsgruppe
LeukemiasStudie
GRAALL 2003, GRAALL 2005Title
Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALLAutoren
Simonin M, Andrieu GP, Birsen R, Balsat M, Hypolite G, Courtois L, Graux C, Grardel N, Cayuela JM, Huguet F, Chalandon Y, Le Bris Y, Macintyre E, Gandemer V, Petit A, Rousselot P, Baruchel A, Bouscary D, Hermine O, Boissel N, Asnafi VImpact-Faktor
10.452Typ
Collaborative group trialsJournal
HAEMATOLOGICAJahr
2023Krankheitsgruppe
LeukemiasStudie
GRAALL 2005Title
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 studyAutoren
Orvain C, Chantepie S, Thomas X, Escofrre-Barbe M, Huguet F, Desbrosses Y, Guillerm G, Uzunov M, Leguay T, Barbieux S, Vey N, Chevallier P, Malfuson JV, Lepretre S, Baumann M, Aykut M, Chaib A, Joris M, Zerazhi H, Stussi G, Chapiro J, Berthon C, Bonmati C, Jourdan E, Carp D, Marcais AR, Gallego-Hernanz MP, Vaida I, Bilger K, Villate A, Pasquier F, Chalandon Y, Maury S, Lheritier V, Ifrah N, Dombret H, Boissel N, Hunault-Berger MImpact-Faktor
11.04Typ
Collaborative group trialsJournal
BLOOD CANCER DISCOVJahr
2023Krankheitsgruppe
LeukemiasStudie
GRAALL 2014Title
Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal HematopoiesisAutoren
Kim R, Bergugnat H, Larcher L, Duchmann M, Passet M, Gachet S, Cuccuini W, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Schafer BW, Delabesse E, Itzykson R, Ades L, Hicheri Y, Chalandon Y, Graux C, Chevallier P, Hunault M, Leguay T, Huguet F, Lheritier V, Dombret H, Soulier J, Rousselot P, Boissel N, Clappier EImpact-Faktor
-Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2023Krankheitsgruppe
LymphomasStudie
HD 16Title
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaAutoren
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DAImpact-Faktor
10.431Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2023Krankheitsgruppe
LymphomasStudie
HD 18Title
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trialAutoren
Ferdinandus J, Müller H, Damaschin C, Jacob AS, Meissner J, Krasniqi F, Mey U, Schöndube D, Thiemer J, Mathas S, Zijlstra J, Greil R, Feuring-Buske M, Markova J, Rüffer JU, Kobe C, Eich HT, Baues C, Fuchs M, Borchmann P, Behringer KImpact-Faktor
50.5Typ
Collaborative group trialsJournal
BLOODJahr
2023Krankheitsgruppe
LymphomasStudie
HD 16, HD 17Title
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studiesAutoren
Eichenauer DA, Bühnen I, Baues C, Kobe C, Kaul H, Greil R, Moccia A, Zijlstra JM, Hertenstein B, Topp MS, Just M, von Tresckow B, Eich HT, Fuchs M, Dietlein M, Hartmann S, Engert A, Borchmann PImpact-Faktor
10.452Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2023Krankheitsgruppe
LymphomasStudie
HOVON 127/ SAKK 37/16Title
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trialAutoren
Chamuleau MED, Stenner F, Chitu DA, Novak U, Minnema MC, Geerts P, Stevens WBC, Zenz T, van Imhoff GW, Wu KL, Demandt AMP, Kersten MJ, Terpstra WE, Tick LW, Deeren D, Van Den Neste E, Gregor M, Veelken H, Böhmer LH, Caspar CB, Mutsaers P, Refos JM, Sewsaran R, Fu L, Seefat RL, Uyl-de Groot CA, Dirnhofer S, Van Den Brand M, de Jong D, Nijland M, Lugtenburg PImpact-Faktor
24.7Typ
Collaborative group trialsJournal
HAEMATOLOGICAJahr
2023Krankheitsgruppe
LeukemiasStudie
HOVON 132Title
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survivalAutoren
Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos JImpact-Faktor
11.047Typ
Collaborative group trialsJournal
BLOODJahr
2023Krankheitsgruppe
LeukemiasStudie
HOVON 132Title
Prospective validation of CD34+CD38- Leukemic Stem Cell frequency in the HOVON-SAKK132 trialAutoren
Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAMA, Fayed MMHE, Kelder A, Oudshoorn-van Marsbergen L, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevicius L, Juliusson G, van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, Cloos JImpact-Faktor
21.0Typ
Collaborative group trialsJournal
BLOOD CANCER JJahr
2023Krankheitsgruppe
LeukemiasStudie
HOVON 135Title
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineAutoren
Hilberink JR, van Zeventer IA, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK); Huls G.Impact-Faktor
8.125Typ
Collaborative group trialsJournal
NEW ENGL J MEDJahr
2023Krankheitsgruppe
Breast CancersStudie
IBCSG 48-14 POSITIVETitle
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast CancerAutoren
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim Jr HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy KJ, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani OImpact-Faktor
176.079Typ
Collaborative group trialsJournal
BR J CANCERJahr
2023Krankheitsgruppe
Gynecological CancersStudie
INOVATYONTitle
INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.Autoren
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda AImpact-Faktor
9.075Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2023Krankheitsgruppe
Gastrointestinal CancersStudie
PROSPECTTitle
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)Autoren
Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O’Reilly E, Meyerhardt JA, Shi Q, Schrag DImpact-Faktor
45.3Typ
Collaborative group trialsJournal
NEW ENGL J MEDJahr
2023Krankheitsgruppe
Gastrointestinal CancersStudie
PROSPECTTitle
Preoperative Treatment of Locally Advanced Rectal CancerAutoren
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O’Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJImpact-Faktor
96.2Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2023Krankheitsgruppe
LymphomasStudie
REMoDL-BTitle
Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to molecular subgroup in the REMoDL-B study with 5 years follow upAutoren
Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, Mamot C, Novak U, McMillan A, Fields P, Collins GP, Stephens R, Cucco F, Sha C, van Hoppe M, Tooze R, Davies JR, Griffiths G, Schuh A, Burton C, Westhead DR, Du MQ, Johnson PWMImpact-Faktor
50.717Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2023Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolAutoren
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigatorsImpact-Faktor
54.433Typ
Swiss Cancer Institute trialsJournal
LANCET ONCOLJahr
2022Krankheitsgruppe
Urogenital CancersStudie
SAKK 01/10Title
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA/B seminoma: SAKK 01/10Autoren
Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold DM, Putora PM, Berthold DR, Zihler D, Zengerling F, Dieing A, Mueller AC, Schaer C, Biaggi C, Gillessen S, Cathomas RImpact-Faktor
54.433Typ
Swiss Cancer Institute trialsJournal
EUR UROL ONCOLJahr
2022Krankheitsgruppe
Urogenital CancersStudie
SAKK 06/14Title
Results of a phase II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin (rBCG) VPM1002BC in patients with high-grade non muscle-invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14Autoren
Rentsch CA, Thalmann GN, Lucca I, Kwiatkowski M, Wirth GJ, Strebel RT, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Torpai R, Bubendorf L, Wicki A, Roth B, Bosshard P, Püschel H, Boll DT, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Hayoz SImpact-Faktor
7.479Typ
Swiss Cancer Institute trialsJournal
INT J RADIAT ONCOL BIOL PHYSJahr
2022Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Adherence to contouring and treatment planning requirements within a multicentric trial -results of the quality assurance of the SAKK 09/10 trialAutoren
Beck M, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Hayoz S, Schär C, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Aebersold DM, Ghadjar P, Pra ADImpact-Faktor
4.495Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2022Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Validation of the Decipher Genomic Classifier in SAKK 09/10: A Phase 3 Randomized Trial of Dose-escalated Salvage Radiotherapy after Radical ProstatectomyAutoren
Dal Pra A, Ghadjar P, Hayoz S, Liu VYT, Spratt DE, Thompson DJS, Davicioni E, Huang HC, Zhao X, Liu Y, Schär C, Gut P, Plasswilm L, Hölscher T, Polat B, Hildebrandt G, Müller AC, Pollack A, Thalmann GN, Zwahlen D, Aebersold DMImpact-Faktor
7.04Typ
Swiss Cancer Institute trialsJournal
CELLJahr
2022Krankheitsgruppe
Lung CancersStudie
SAKK 16/14Title
Magnesium sensing via LFA-1 regulates CD8+ T cell effector functionAutoren
Lötscher J, Martí I Líndez AA, Kirchhammer N, Cribioli E, Giordano Attianese GMP, Trefny MP, Lenz M, Rothschild SI, Strati P, Künzli M, Lotter C, Schenk SH, Dehio P, Löliger J, Litzler L, Schreiner D, Koch V, Page N, Lee D, Grählert J, Kuzmin D, Burgener AV, Merkler D, Pless M, Balmer ML, Reith W, Huwyler J, Irving M, King CG, Zippelius A, Hess CImpact-Faktor
41.582Typ
Swiss Cancer Institute trialsJournal
J THORAC CARDIOVASC SURGJahr
2022Krankheitsgruppe
Lung CancersStudie
SAKK 16/96, SAKK 16/00, SAKK 16/01Title
Extended resection for potentially operable stage III NSCLC patients after neoadjuvant treatmentAutoren
Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, Krueger T, Perentes JY, Schmid RA, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel RA, Rothschild SI, Hayoz S, Opitz I.Impact-Faktor
5.209Typ
Swiss Cancer Institute trialsJournal
ESMO OPENJahr
2022Krankheitsgruppe
Lung CancersStudie
SAKK 16/96, SAKK 16/00, SAKK 16/01, SAKK 16/08Title
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era. Results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsAutoren
König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild SI, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet EI, Hayoz S, Thierstein S, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh MImpact-Faktor
5.329Typ
Swiss Cancer Institute trialsJournal
JTO CLIN RES REPJahr
2022Krankheitsgruppe
Lung CancersStudie
SAKK 17/04Title
Viral mimicry response is associated with clinical outcome in pleural mesotheliomaAutoren
Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco EImpact-Faktor
-Typ
Swiss Cancer Institute trialsJournal
ESMO OPENJahr
2022Krankheitsgruppe
Lung CancersStudie
SAKK 17/16Title
Long term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): Follow-up efficacy and translational part of the SAKK 17/16 studyAutoren
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali P, Ceresoli GL, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas YImpact-Faktor
5.329Typ
Swiss Cancer Institute trialsJournal
LUNG CANCERJahr
2022Krankheitsgruppe
Lung CancersStudie
SAKK 19/18Title
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: the SAKK 19/18 phase II studyAutoren
Addeo A, Rothschild SI, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann PM, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh MImpact-Faktor
6.081Typ
Swiss Cancer Institute trialsJournal
ENDOCRINE ONCOLOGYJahr
2022Krankheitsgruppe
Breast CancersStudie
SAKK 21/12Title
SAKK 21/12 - A stratified, multicenter Phase II trial of transdermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancerAutoren
Vetter M, Rothgiesser KM, Qiyu L, Hawle H, Schönfeld W, Ribi K, Riniker S, von Moos R, Trojan A, Kralidis E, Fehr M, Müller A, Thuerlimann BImpact-Faktor
-Typ
Swiss Cancer Institute trialsJournal
J GERIATR ONCOLJahr
2022Krankheitsgruppe
Breast CancersStudie
SAKK 25/14Title
Eribulin as first-line treatment in elderly patients (=70years) with advanced breast cancer: a multicenter Phase II trial [SAKK 25/14]Autoren
Hasler-Strub U, Mueller A, Li Q, Thuerlimann B, Ribi K, Gerber S, von Moos R, Fehr M, Rochlitz C, Zaman K, Aebi S, Hochstrasser A, Gick U, Baertschi D, Greuter S, Schreiber A, Caspar C, Trojan A, Condorelli R, Ruhstaller TImpact-Faktor
3.929Typ
Swiss Cancer Institute trialsJournal
BLOOD ADVJahr
2022Krankheitsgruppe
LymphomasStudie
SAKK 35/15Title
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAutoren
Stathis A, Mey UJM, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle DL, Hess D, Moccia AA, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann WImpact-Faktor
6.799Typ
Swiss Cancer Institute trialsJournal
CANCERSJahr
2022Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Integration of baseline metabolic parameters and mutational profile predict long-term response to first-line therapy in DLBCL patients. A post hoc analysis of SAKK38/07 study (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) parameters, combined with mutaAutoren
Genta S, Ghilardi G, Cascione L, Juskevicius D, Tzankov A, Schär S, Milan L, Pirosa MC, Esposito F, Ruberto T, Giovanella L, Hayoz S, Mamot C, Dirnhofer S, Zucca E, Ceriani LImpact-Faktor
6.639Typ
Swiss Cancer Institute trialsJournal
BJCPJahr
2022Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 41/16Title
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)Autoren
Schmulenson E, Bovet C, Theurillat R, Decosterd LA, Largiadèr CR, Prost JC, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Joerger M, Jaehde UImpact-Faktor
3.716Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2022Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 75/08Title
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trialAutoren
Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner AD, Girschikofsky M, Eboulet E, Stahl M, Ruhstaller TImpact-Faktor
9.162Typ
Swiss Cancer Institute trialsJournal
CANCERSJahr
2022Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 80/20_CaSATitle
Outcome and prognostic factors of COVID-19 infection in Swiss cancer patients: Final results of SAKK 80/20 (CaSA)Autoren
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, Stathis A, von Moos RImpact-Faktor
6.162Typ
Swiss Cancer Institute servicesJournal
EUR UROL OPEN SCIJahr
2022Krankheitsgruppe
Urogenital CancersStudie
-Title
Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical ProstatectomyAutoren
Oezdemir BC, Arnold N, Fleischmann A, Hensel J, Klima I, Kruithof-de Julio M, Burkhard F, Hayoz S, Kiss B, Thalmann GMImpact-Faktor
3.0Typ
Swiss Cancer Institute servicesJournal
BIOLOGYJahr
2022Krankheitsgruppe
MelanomasStudie
-Title
Prescription patterns, recurrence and toxicity rates of adjuvant treatment for stage III/IV melanoma- A real world single-centre analysisAutoren
Hoffmann M, Hayoz S, Özdemir B CImpact-Faktor
5.007Typ
Swiss Cancer Institute servicesJournal
J CANCER RES CLIN ONCOLJahr
2022Krankheitsgruppe
-Studie
-Title
The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sexAutoren
Wahli MN, Hayoz S, Hoch D, Ryser CO, Hoffmann M, Scherz A, Schwacha-Eipper B, Häfliger S, Wampfler J, Berger MD, Novak U, Özdemir BCImpact-Faktor
4.322Typ
Collaborative group trialsJournal
LUNG CANCERJahr
2022Krankheitsgruppe
Lung CancersStudie
ETOP ALERTTitle
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialAutoren
Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans A-MC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R.Impact-Faktor
6.081Typ
Collaborative group trialsJournal
ESMO OPENJahr
2022Krankheitsgruppe
Lung CancersStudie
ETOP BOOSTERTitle
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC – A systematic review and meta-analysisAutoren
Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Sala MA, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RAImpact-Faktor
6.54Typ
Collaborative group trialsJournal
LUNG CANCERJahr
2022Krankheitsgruppe
Lung CancersStudie
ETOP PROMISE-mesoTitle
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9 15 PROMISE-meso phase III trialAutoren
Banna G L, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RAImpact-Faktor
5.705Typ
Collaborative group trialsJournal
LUNG CANCERJahr
2022Krankheitsgruppe
Lung CancersStudie
ETOP SPLENDOURTitle
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.Autoren
Peters S, Letovanec I, Mauer, M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth,A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, Stahel RAImpact-Faktor
3.958Typ
Collaborative group trialsJournal
BMC CANCERJahr
2022Krankheitsgruppe
LymphomasStudie
HD 16Title
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trialAutoren
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin CA, Kobe CImpact-Faktor
4.638Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2022Krankheitsgruppe
LeukemiasStudie
HOVON 103 - SELTitle
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with AML and high risk MDSAutoren
Janssen JJWM, Löwenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele GJImpact-Faktor
11.528Typ
Collaborative group trialsJournal
FRONT ONCOLJahr
2022Krankheitsgruppe
LeukemiasStudie
HOVON 92, HOVON 102, HOVON 103, HOVON 132Title
Concordance in Measurable Residual Disease result and outcome after first- and second induction cycle in Acute Myeloid LeukemiaAutoren
Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJImpact-Faktor
6.244Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2022Krankheitsgruppe
Breast CancersStudie
IBCSG 24-02Title
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFTAutoren
Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM, for the SOFT Investigators and the International Breast Cancer Study GroupImpact-Faktor
50.717Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2022Krankheitsgruppe
Breast CancersStudie
IBCSG 24-02, IBCSG 25-02Title
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT TrialsAutoren
Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PAImpact-Faktor
50.717Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2022Krankheitsgruppe
Breast CancersStudie
IBCSG 24-02, IBCSG 25-02Title
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trialsAutoren
Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C, Bergh J, Swain S, Francis PA, Gnant M, Perrone F, Regan MMImpact-Faktor
41.316Typ
Collaborative group trialsJournal
LANCETJahr
2022Krankheitsgruppe
Breast CancersStudie
IBCSG 38-10Title
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 studyAutoren
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu T TT, Muanza TM, Neal A, Olivotto IA, BIG 3–07/TROG 07.01 trial investigatorsImpact-Faktor
202.731Typ
Collaborative group trialsJournal
JAMAJahr
2022Krankheitsgruppe
Breast CancersStudie
IBCSG 40-11Title
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialAutoren
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WRImpact-Faktor
56.272Typ
Collaborative group trialsJournal
INT J CANCERJahr
2022Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)Autoren
James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz-Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russell JM, Berthold DR, Buckner ML, Mason MD, Ritchie AWS, Birtle AJ, Brock SJ, Das P, Ford D, Gale J, Grant W, Gray EK, Hoskin P, Khan MM, Manetta C, McPhail NJ, O'Sullivan JM, Parikh O, Perna C, Pezaro CJ, Protheroe AS, Robinson AJ, Rudman SM, Sheehan DJ, Srihari NN, Syndikus I, Tanguay JS, Thomas CW, Vengalil S, Wagstaff J, Wylie JP, Parmar MKB, Sydes MRImpact-Faktor
7.316Typ
Collaborative group trialsJournal
JNCI CANCER SPECTRJahr
2022Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialAutoren
James ND, Ingleby FC, Clarke NW, Amos CL, Attard G, Brawley CD, Chowdhury S, Cross W, Dearnaley DP, Gilbert DC, Gillessen S, Jones RJ, Langley RE, Macnair A, Malik ZI, Mason MD, Matheson DJ, Millman R, Parker CC, Rush HL, Russell JM, Au C, Ritchie AWS, Mestre RP, Ahmed I, Birtle AJ, Brock SJ, Das P, Ford VA, Gray EK, Hughes RJ, Manetta CB, McLaren DB, Nikapota AD, O'Sullivan JM, Perna C, Peedell C, Protheroe AS, Sundar S, Tanguay JS, Tolan SP, Wagstaff J, Wallace JB, Wylie JP, Zarkar A, Parmar MKB, Sydes MR.Impact-Faktor
-Typ
Swiss Cancer Institute trialsJournal
EUR UROLJahr
2021Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Dose-intensified versus conventional dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomised phase 3 trialAutoren
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Gomez S, Wust P, Thalmann GN, Aebersold DMImpact-Faktor
13.938Typ
Swiss Cancer Institute trialsJournal
BR J RADIOLJahr
2021Krankheitsgruppe
Lung CancersStudie
SAKK 16/00Title
Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue typesAutoren
Denzler S, Vuong D, Bogowicz M, Pavic M, Frauenfelder T, Thierstein S, Eboulet EI, Maurer B, Schniering J, Gabrys HS, Schmitt-Opitz I, Pless M, Foerster R, Guckenberger M, Tanadini-Lang S.Impact-Faktor
2.196Typ
Swiss Cancer Institute trialsJournal
EJNMMI RESEARCHJahr
2021Krankheitsgruppe
Lung CancersStudie
SAKK 16/00Title
Preselection of robust radiomics features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imagingAutoren
Oliveira C, Amstutz F, Vuong D, Bogowicz M, Hüllner M, Foerster R, Basler L, Schröder C, Eboulet EI, Pless M, Thierstein S, Peters S, Hillinger S, Tanadini-Lang S, Guckenberger M.Impact-Faktor
2.73Typ
Swiss Cancer Institute trialsJournal
SCI REPJahr
2021Krankheitsgruppe
Lung CancersStudie
SAKK 16/00Title
Quantification of spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLCAutoren
Vuong D, Bogowicz M, Wee L, Riesterer O, Vlaskou Badra E, D'Cruz LA, Balermpas P, van Timmeren JE, Burgermeister S, Dekker A, De Ruysscher D, Unkelbach J, Thierstein S, Eboulet EI, Peters S, Pless M, Guckenberger M, Tanadini-Lang S.Impact-Faktor
4.379Typ
Swiss Cancer Institute trialsJournal
J CLIN ONCOLJahr
2021Krankheitsgruppe
Lung CancersStudie
SAKK 16/14Title
SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer — A multicentre single-arm phase II trial.Autoren
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless MImpact-Faktor
18.428Typ
Swiss Cancer Institute trialsJournal
LUNG CANCERJahr
2021Krankheitsgruppe
Lung CancersStudie
SAKK 19/16Title
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.Autoren
Froesch P, Mark M, Rothschild SI, Li Q, Godar G, Rusterholz C, Oppliger Leibundgut E, Schmid S, Colombo I, Metaxas Y, König D, Sessa C, Gautschi O, Früh MImpact-Faktor
3.958Typ
Swiss Cancer Institute trialsJournal
THE BREASTJahr
2021Krankheitsgruppe
Breast CancersStudie
SAKK 23/16Title
Implementation of Tailored Axillary Surgery for Patients with Clinically Node-Positive Breast Cancer: Prospective Study within SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101Autoren
Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Seiler S, Maddox C, Ruhstaller T, Muenst S, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Kurzeder C, Újhelyi M, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Dubsky P, Exner R, Fansa H, Hager C, Reisenberger K, Singer CF, Reitsamer R, Reinisch M, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Fitzal F, Nussbaumer R, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer MImpact-Faktor
4.38Typ
Swiss Cancer Institute trialsJournal
CLIN LYMPHOMA MYELOMA LEUKJahr
2021Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell LymphomaAutoren
Greuter M, Eertink JJ, Jongeneel G, Dührsen U, Hüttmann A, Schmitz C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Carr R, Györke T, Burggraaff CN, de Vet H, Hoekstra OS, Zijlstra JM, Coupé V; PETRA consortiumImpact-Faktor
3.231Typ
Swiss Cancer Institute trialsJournal
HEMATOL ONCOLJahr
2021Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysisAutoren
Ceriani L, Milan L, Cascione L, Gritti G, Dalmasso F, Esposito F, Pirosa MC, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca EImpact-Faktor
3.084Typ
Swiss Cancer Institute trialsJournal
BLOOD ADVJahr
2021Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patientsAutoren
Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Hüttmann A, Schmitz C, Müller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Györke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCWImpact-Faktor
4.91Typ
Swiss Cancer Institute trialsJournal
SWISS MED WKLYJahr
2021Krankheitsgruppe
Supportive CareStudie
SAKK 95/16Title
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate studyAutoren
Stoffel ST, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MTImpact-Faktor
1.821Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2021Krankheitsgruppe
Supportive CareStudie
SAKK 95/16Title
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)Autoren
Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar C, Moos R, Mark MImpact-Faktor
7.04Typ
OtherJournal
EUR J HEALTH ECONJahr
2021Krankheitsgruppe
Lung CancersStudie
-Title
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with advanced non-small cell lung cancer and high PD-L1 expression in Switzerland.Autoren
Barbier MC, Pardo E, Panje CM, Gautschi O, Lupatsch JEImpact-Faktor
2.367Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2021Krankheitsgruppe
Lung CancersStudie
ETOP BOOSTERTitle
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialAutoren
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Pulla MP, Campelo RG, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER CollaboratorsImpact-Faktor
32.976Typ
Collaborative group trialsJournal
LUNG CANCERJahr
2021Krankheitsgruppe
Lung CancersStudie
ETOP SPLENDOURTitle
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsAutoren
Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M.Impact-Faktor
3.958Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2021Krankheitsgruppe
LymphomasStudie
HD 14Title
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Autoren
Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B.Impact-Faktor
10.406Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2021Krankheitsgruppe
LymphomasStudie
HD 17Title
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialAutoren
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A.Impact-Faktor
41.316Typ
Collaborative group trialsJournal
BR J HAEMATOLJahr
2021Krankheitsgruppe
LymphomasStudie
HD 18Title
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphomaAutoren
Kreissl S, Voltin CA, Kaul H, Bühnen I, Mettler J, Pabst T, Eichenauer DA, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Kobe C.Impact-Faktor
5.67Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2021Krankheitsgruppe
LymphomasStudie
HD 18Title
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialAutoren
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann PImpact-Faktor
18.959Typ
Collaborative group trialsJournal
CANCERSJahr
2021Krankheitsgruppe
LeukemiasStudie
HOVON 102Title
AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AMLAutoren
Hanekamp D, Tettero JM, Ossenkoppele GJ, Kelder A, Cloos J, Schuurhuis GJImpact-Faktor
6.639Typ
Collaborative group trialsJournal
CANCER MEDJahr
2021Krankheitsgruppe
LeukemiasStudie
HOVON 102Title
The added value of multi-state modelling in a randomized controlled trial: the HOVON 102 study re-analyzedAutoren
Bakunina K, Putter H, Versluis J, Koster EAS, van der Holt B, Manz MG, Breems DA, Gjertsen BT, Cloos J, Valk PJM, Passweg J, Pabst T, Ossenkoppele GJ, Löwenberg B, Cornelissen JJ, de Wreede LCImpact-Faktor
3.362Typ
Collaborative group trialsJournal
ANN HEMATOLJahr
2021Krankheitsgruppe
LeukemiasStudie
HOVON 103 - LENTitle
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortAutoren
Brune MM, Stüssi G, Lundberg P, Vela V, Heim D, Manz MG, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Grobholz R, Fehr M, Cogliatti S, Ossenkoppele GJ, Löwenberg B, Rudolf CB, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov AImpact-Faktor
2.904Typ
Collaborative group trialsJournal
CANCERSJahr
2021Krankheitsgruppe
LeukemiasStudie
HOVON 103 - TOSTitle
Addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with AML and high risk MDSAutoren
Janssen J, Löwenberg B, Manz M, Bargetzi M, Biemond B, Borne PVD, Breems D, Brouwer R, Chalandon Y, Deeren D, Efthymiou A, Gjertsen BT, Graux C, Gregor M, Heim D, Hess U, Hoogendoorn M, Jaspers A, Jie A, Jongen-Lavrencic M, Klein S, Klift MV, Kuball J, Lammeren-Venema DV, Legdeur MC, Loosdrecht AV, Maertens J, Kooy MVM, Moors I, Nijziel M, Obbergh FV, Oosterveld M, Pabst T, Poel MV, Sinnige H, Spertini O, Terpstra W, Tick L, Velden WV, Vekemans MC, Vellenga E, Weerdt O, Westerweel P, Stüssi G, Norden YV, Ossenkoppele G.Impact-Faktor
6.126Typ
Collaborative group trialsJournal
BLOOD ADVJahr
2021Krankheitsgruppe
LeukemiasStudie
HOVON 132Title
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trialAutoren
Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M, Silzle T, van Lammeren-Venema D, Moors I, Breems DA, Hoogendoorn M, Legdeur MJC, Fischer T, Kuball J, Cornelissen J, Porkka K, Juliusson G, Meyer P, Höglund M, Gjertsen BT, Janssen JJWM, Huls G, Passweg J, Cloos J, Valk PJM, van Elssen CHMJ, Manz MG, Floisand Y, Ossenkoppele GJ.Impact-Faktor
4.91Typ
Collaborative group trialsJournal
CANCERJahr
2021Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialAutoren
Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, Giobbie-Hurder A, Gelber RD, Ejlertsen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Goldhirsch A, Di Leo A, Colleoni M, Vaz-Luis I, Lin NU.Impact-Faktor
5.742Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2021Krankheitsgruppe
Breast CancersStudie
IBCSG 35-07Title
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyAutoren
Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas MP, Simoncini E, Abdi E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Gombos A, Ruhstaller T, Burstein HJ, Rabaglio M, Ruepp B, Ribi K, Viale G, Gelber RD, Coates AS, Loi S, Goldhirsch A, Regan MM, Colleoni M; SOLE InvestigatorsImpact-Faktor
32.976Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2021Krankheitsgruppe
Breast CancersStudie
IBCSG 52-15 PALLASTitle
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyAutoren
Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M.Impact-Faktor
41.316Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2021Krankheitsgruppe
LymphomasStudie
IELSG-42Title
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trialAutoren
Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JEC, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski KImpact-Faktor
10.406Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2021Krankheitsgruppe
Lung CancersStudie
Lung ART EORTCTitle
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trialAutoren
Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcman G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, Dunant A, Edwards JG, Thomas PA, Mercier O, Bardet A.Impact-Faktor
24.69Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2021Krankheitsgruppe
Gynecological CancersStudie
Mito/Mango 16bTitle
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialAutoren
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone FImpact-Faktor
41.316Typ
Collaborative group trialsJournal
LANCETJahr
2021Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolAutoren
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James NDImpact-Faktor
79.321Typ
Swiss Cancer Institute trialsJournal
ONCOIMMUNOLOGYJahr
2020Krankheitsgruppe
Urogenital CancersStudie
SAKK 06/14Title
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapyAutoren
Rentsch CA, Bosshard P, Mayor G, Rieken M, Püschel H, Wirth G, Cathomas R, Parzmair GP, Grode L, Eisele B, Sharma H, Gupta M, Gairola S, Shaligram U, Goldenberger D, Spertini F, Audran R, Enoiu M, Berardi S, Hayoz S, Wicki AImpact-Faktor
5.333Typ
Swiss Cancer Institute trialsJournal
INT J RADIAT ONCOL BIOL PHYSJahr
2020Krankheitsgruppe
Lung CancersStudie
SAKK 15/12Title
Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurotoxicity and quality of life in patients with limited disease small-cell lung cancer. A multicenter phase II trial (SAKK 15/12)Autoren
Vees H, Caparrotti F, Eboulet EI, Xyrafas A, Fuhrer A, Meier U, Mark M, Elicin O, Aebersold DM, Zwahlen DR, Finazzi T, Allal AS, Putora PM, Martucci F, Rudolf CB, Ribi KImpact-Faktor
6.203Typ
Swiss Cancer Institute trialsJournal
MED PHYSJahr
2020Krankheitsgruppe
Lung CancersStudie
SAKK 16/00Title
Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patientsAutoren
Vuong D, Bogowicz M, Denzler S, Oliveira C, Foerster R, Amstutz F, Gabrys HS, Unkelbach J, Hillinger S, Thierstein S, Xyrafas A, Peters S, Pless M, Guckenberger M, Tanadini-Lang S.Impact-Faktor
3.177Typ
Swiss Cancer Institute trialsJournal
FRONT ONCOLJahr
2020Krankheitsgruppe
Lung CancersStudie
SAKK 16/00Title
Radiomics feature activation maps as a new tool for signature interpretability” for the special issue “Breakthrough in Imaging-Guided Precision Medicine in OncologyAutoren
Vuong D, Tanadini-Lang S, Wu Z, Marks R, Unkelbach J, Hillinger S, Eboulet EI, Thierstein S, Peters S, Pless M, Guckenberger M, Bogowicz M.Impact-Faktor
4.848Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2020Krankheitsgruppe
Lung CancersStudie
SAKK 17/16Title
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Autoren
Metaxas Y, Früh M, Eboulet E I, Grosso F, Pless M, Zucali P A, Ceresoli G L, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C,. Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos RImpact-Faktor
14.196Typ
Swiss Cancer Institute trialsJournal
CANCER IMMUNOL IMMUNJahr
2020Krankheitsgruppe
Lung CancersStudie
SAKK 19/09Title
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: An analysis of pre and post treatment biopsies in the multi-center SAKK19/09 study.Autoren
Amrein MA, Bührer ED, Amrein ML, Li Q, Rothschild S, Riether C, Jaggi R, Savic-Prince S, Bubendorf L, Gautschi O, Ochsenbein AF.Impact-Faktor
4.711Typ
Swiss Cancer Institute trialsJournal
CANCER IMMUNOL IMMUNJahr
2020Krankheitsgruppe
Lung CancersStudie
SAKK 19/17Title
SAKK 19/17 - Is First-Line Durvalumab in Patients with PD-L1 Positive, Advanced Non-Small Cell Lung Cancer with a Performance Status of 2 Safe?Autoren
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh MImpact-Faktor
5.442Typ
Swiss Cancer Institute trialsJournal
BMC CANCERJahr
2020Krankheitsgruppe
Breast CancersStudie
SAKK 22/99Title
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.Autoren
Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle DA, Rothgiesser K, Pagani O, Thürlimann B.Impact-Faktor
2.933Typ
Swiss Cancer Institute trialsJournal
BLOOD ADVJahr
2020Krankheitsgruppe
LeukemiasStudie
SAKK 32/93, SAKK 32/95, SAKK 32/98Title
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia - A SAKK trialAutoren
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Mey U, Blum S, Rauch D, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Li Q, Feller A, Stussi G.Impact-Faktor
4.91Typ
Swiss Cancer Institute trialsJournal
BLOOD ADVJahr
2020Krankheitsgruppe
LeukemiasStudie
SAKK 33/18Title
Guideline-based indicators for adult patients with myelodysplastic syndromesAutoren
Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Cermák J, Dinmohamed AG, Eeltink C, Eggmann S, Fenaux P, Germing U, Haschke M, Hellstrom-Lindberg E, Heger M, van de Loosdrecht AA, Passweg J, Pfeilstöcker M, Platzbecker U, Malcovati L, de Almeida AM, Mittelman M, Morgenthaler C, Steensma DP, Santini V, Stauder R, Symeonidis A, Schär S, Maddox C, de Witte T, Bohlius J, Bonadies NImpact-Faktor
4.91Typ
Swiss Cancer Institute trialsJournal
BLOOD ADVJahr
2020Krankheitsgruppe
LymphomasStudie
SAKK 35/03Title
Prolonged rituximab maintenance in follicular lymphoma patients: Long-term results of the SAKK 35/03 randomized trialAutoren
Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca EImpact-Faktor
4.91Typ
Swiss Cancer Institute trialsJournal
BRIT J HAEMATOLJahr
2020Krankheitsgruppe
LymphomasStudie
SAKK 35/10Title
Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trialAutoren
Menter T, Hayoz S, Zucca E, Kimby E, Dirnhofer S, Tzankov A.Impact-Faktor
5.401Typ
Swiss Cancer Institute trialsJournal
BRIT J HAEMATOLJahr
2020Krankheitsgruppe
LymphomasStudie
SAKK 35/10Title
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapyAutoren
Menter T, Tzankov A, Zucca E, Kimby E, Hultdin M, Sundström C, Beiske K, Cogliatti S, Banz Y, Cathomas G, Karjalainen-Lindsberg ML, Grobholz R, Mazzucchelli L, Sander B, Hawle H, Hayoz S, Dirnhofer SImpact-Faktor
5.206Typ
Swiss Cancer Institute trialsJournal
BRIT J HAEMATOLJahr
2020Krankheitsgruppe
LymphomasStudie
SAKK 35/98, SAKK 35/03, SAKK 35/10Title
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)Autoren
Moccia AA , Schär S, Hayoz S, Pirosa MC, Taverna C, Novak U, Kimby E, Ghielmini M, Zucca EImpact-Faktor
5.67Typ
Swiss Cancer Institute trialsJournal
HEMATOL ONCOLJahr
2020Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trialAutoren
Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani LImpact-Faktor
3.084Typ
Swiss Cancer Institute trialsJournal
BLOOD ADVJahr
2020Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic modelAutoren
Ceriani L, Gritti G, Cascione L, Pirosa MC, Polino A, Ruberto T, Stathis A, Bruno A, Moccia AA, Giovanella L, Hayoz S, Schär S, Dirnhofer S, Rambaldi A, Martinelli G, Mamot C, Zucca EImpact-Faktor
4.584Typ
Swiss Cancer Institute trialsJournal
BMC CANCERJahr
2020Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 75/08Title
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.Autoren
Fehr M, Hawle H, Hayoz S, Thuss-Patience P, Schacher S, Riera Knorrenschild J, Dürr D, Knoefel WT, Rumpold H, Bitzer M, Zweifel M, Samaras P, Mey U, Küng M, Winterhalder R, Eisterer W, Hess V, Gérard MA, Templeton A, Stahl M, Ruhstaller TImpact-Faktor
3.362Typ
Swiss Cancer Institute trialsJournal
ANN SURGJahr
2020Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 75/08Title
Surgical outcomes after neoadjuvant chemoradiation followed by curative surgery in patients with esophageal cancer: An intergroup phase lll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08)Autoren
von Holzen U, Schmidt S, Hayoz S, Steffen T, Grieder F, Bartsch D, Schnider A, Knoefel WT, Piessen G, Kettelhack C, Marti WR, Schäfer M, Függer R, Königsrainer A, Gloor B, Furrer M, Gérard MA, Hawle H, Walz MK, Alesina P, Ruhstaller TImpact-Faktor
10.13Typ
Swiss Cancer Institute servicesJournal
BONE MARROW TRANSPLJahr
2020Krankheitsgruppe
LymphomasStudie
-Title
A randomized evaluation of vinorelbine versus gemcitabinechemotherapy mobilization of stem cells in myeloma patientsAutoren
Jeker B, Farag S, Taleghani BM, Novak U, Mueller BU, Li Q, Betticher D, Luethi JM, Farese S, Ruefer A, Bacher U, Pabst T.Impact-Faktor
3.57Typ
Swiss Cancer Institute servicesJournal
JAMA NETW OPENJahr
2020Krankheitsgruppe
Urogenital CancersStudie
-Title
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene AberrationsAutoren
Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen SImpact-Faktor
5.032Typ
Swiss Cancer Institute servicesJournal
CANCER IMMUNOL IMMUNJahr
2020Krankheitsgruppe
Lung CancersStudie
-Title
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortAutoren
Schmid S, Mauti LA, Friedlaender A, Blum V, Rothschild SI, Bouchaab H, Frösch P, Britschgi C, König D, Wannesson L, Janthur WD, Schär S, Demmer I, Addeo A, Jochum W, Früh MImpact-Faktor
4.9Typ
OtherJournal
ANN ONCOLJahr
2020Krankheitsgruppe
Lung CancersStudie
-Title
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in SwitzerlandAutoren
Panje CM, Lupatsch JE, Barbier M, Pardo E, Lorez M, Dedes KJ, Aebersold DM, Plasswilm L, Gautschi O, Schwenkglenks MImpact-Faktor
7.04Typ
Collaborative group trialsJournal
INT J GYNECOL CANCERJahr
2020Krankheitsgruppe
Gynecological CancersStudie
Ago-Ovar_2.29Title
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Autoren
Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F.Impact-Faktor
2.095Typ
Collaborative group trialsJournal
HEMASPHEREJahr
2020Krankheitsgruppe
LeukemiasStudie
CLL 10Title
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)Autoren
Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst BImpact-Faktor
-Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2020Krankheitsgruppe
LeukemiasStudie
CLL 7Title
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialAutoren
Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Busch R, Porcher R, Cazin B, Dreyfus B, Ibach S, Leprêtre S, Fischer K, Kaiser F, Eichhorst B, Wentner CM, Hoechstetter MA, Döhner H, Leblond V, Kneba M, Letestu R, Böttcher S, Stilgenbauer S, Hallek M, Levy VImpact-Faktor
8.665Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2020Krankheitsgruppe
LeukemiasStudie
CML-IVTitle
High-risk additional chromosomal abnormalities at low blast counts herald death by CMLAutoren
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani MImpact-Faktor
10.431Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2020Krankheitsgruppe
LymphomasStudie
EMN-02 Hovon 95Title
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.Autoren
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld PImpact-Faktor
10.698Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2020Krankheitsgruppe
Lung CancersStudie
ETOP PROMISE-mesoTitle
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trialAutoren
Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, López Castro R, García Campelo R, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, Stahel RA.Impact-Faktor
18.274Typ
Collaborative group trialsJournal
J THORAC ONCOLJahr
2020Krankheitsgruppe
Lung CancersStudie
ETOP SPLENDOURTitle
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR TrialAutoren
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, Stahel RA.Impact-Faktor
13.357Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2020Krankheitsgruppe
LeukemiasStudie
GRAALL 2005Title
Adult T-cell Acute Lymphoblastic Leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantationAutoren
Kim R, Boissel N, Touzart A, Leguay T, Thonier F, Thomas X, Raffoux E, Huguet F, Villarese P, Fourrage C, Passini L, Hunault M, Lepretre S, Chevallier P, Braun T, Lhéritier V, Chantepie S, Maury S, Escoffre M, Tavernier E, Chalandon Y, Graux C, Macintyre E, Ifrah N, Asnafi V, Dombret H, Lhermitte L; on behalf the GRAALL groupImpact-Faktor
9.944Typ
Collaborative group trialsJournal
BLOODJahr
2020Krankheitsgruppe
LeukemiasStudie
GRAALL 2005Title
Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 StudyAutoren
Orvain C, Balsat M, Tavernier E, Marolleau JP, Pabst T, Chevallier P, de Gunzburg N, Cacheux V, Rigal-Huguet F, Chantepie SP, Caillot D, Chalandon Y, Frayfer J, Bonmati C, Lheritier V, Ifrah NH, Dombret H, Boissel N, Hunault-Berger MMImpact-Faktor
10.452Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2020Krankheitsgruppe
LymphomasStudie
HD 10, HD 13Title
Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes with Conventional or High-Dose ChemotherapyAutoren
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert AImpact-Faktor
18.428Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2020Krankheitsgruppe
LeukemiasStudie
HD 13, HD 14, HD 15Title
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupAutoren
Kreissl S, Müller H, Goergen H, Meissner J, Topp M, Sökler M, Markova J, Bernhard J, Greil R, von Tresckow B, Behringer K, Rüffer JU, Flechtner HH, Möstl M, Fuchs M, Engert A, Diehl V, Borchmann P.Impact-Faktor
32.956Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2020Krankheitsgruppe
LeukemiasStudie
HOVON 103 - LENTitle
Lenalidomide added to standard intensive treatment for elderly patients with AML and high risk MDSAutoren
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Micheaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg BImpact-Faktor
10.431Typ
Collaborative group trialsJournal
BLOOD ADVJahr
2020Krankheitsgruppe
LeukemiasStudie
HOVON 135Title
Ibrutinib added to 10-day decitabine for older patients with AML and higher-risk MDSAutoren
Huls G, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, van Zeventer I, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJImpact-Faktor
4.91Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2020Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trialAutoren
Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates AS, Gelber RD, Goldhirsch A, Colleoni M, Thürlimann B, Regan MM.Impact-Faktor
3.94Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2020Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 studyAutoren
Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, Hackl W, Thuerlimann B, Viale G, Di Leo A, Colleoni M, Regan MM, Loi S.Impact-Faktor
18.274Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2020Krankheitsgruppe
LymphomasStudie
T-Cell ProjectTitle
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.Autoren
Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, Kim SJ, Cabrera ME, Shustov AR, Chiattone CS, Horwitz SM, Dlouhy I, Spina M, Hitz F, Montoto S, Nagler A, Martinez V, De Souza CA, Fernandez-Alvarez R, Ballova V, Gabús R, Inghirami G, Federico M, Kim WSImpact-Faktor
10.698Typ
Swiss Cancer Institute trialsJournal
CANCERSJahr
2019Krankheitsgruppe
Urogenital CancersStudie
SAKK 08/14Title
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).Autoren
Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic TImpact-Faktor
5.326Typ
Swiss Cancer Institute trialsJournal
BR J CANCERJahr
2019Krankheitsgruppe
Lung CancersStudie
SAKK 16/08Title
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC. A multicenter phase II trial (SAKK 16/08)Autoren
Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters SImpact-Faktor
5.282Typ
Swiss Cancer Institute trialsJournal
RADIOTHER ONCOLJahr
2019Krankheitsgruppe
Lung CancersStudie
SAKK 17/04Title
Pattern of Failure after Adjuvant Radiotherapy Following Extrapleural Pneumonectomy of Pleural Mesothelioma in the SAKK 17/04 TrialAutoren
Riesterer O, Frank Ciernik I, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl JImpact-Faktor
4.363Typ
Swiss Cancer Institute trialsJournal
NON-CODING RNAJahr
2019Krankheitsgruppe
Lung CancersStudie
SAKK 17/04Title
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.Autoren
Kresoja-Rakic J, Szpechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E.Impact-Faktor
-Typ
Swiss Cancer Institute trialsJournal
BMC CANCERJahr
2019Krankheitsgruppe
Breast CancersStudie
SAKK 22/99Title
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival dataAutoren
Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T.Impact-Faktor
3.362Typ
Swiss Cancer Institute trialsJournal
SCI REPJahr
2019Krankheitsgruppe
Breast CancersStudie
SAKK 28/12Title
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort.Autoren
Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille JC, Hawle H, Klingbiel D, Thuerlimann B, Ruhstaller T.Impact-Faktor
4.525Typ
Swiss Cancer Institute trialsJournal
BLOODJahr
2019Krankheitsgruppe
LymphomasStudie
SAKK 35/10Title
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.Autoren
Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Berardi Vilei S, Ghielmini M, Kimby EImpact-Faktor
10.452Typ
Swiss Cancer Institute trialsJournal
BLOOD CANCER JJahr
2019Krankheitsgruppe
LymphomasStudie
SAKK 39/10Title
Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial (SAKK 39/10)Autoren
Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen CImpact-Faktor
8.125Typ
Swiss Cancer Institute trialsJournal
ANN SURG ONCOLJahr
2019Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 40/04Title
ASO Author Reflections: What is the Impact of Different Rectal Reconstruction Techniques After Total Mesorectal Excision on Quality of Life?Autoren
Ribi K, Bernhard J.Impact-Faktor
3.93Typ
Swiss Cancer Institute trialsJournal
ANN SURG ONCOLJahr
2019Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 40/04Title
Quality of Life After Total Mesorectal Excision and Rectal Replacement: Comparing Side-to-End, Colon J-Pouch and Straight Colorectal Reconstruction in a Randomized, Phase III Trial (SAKK40/04)Autoren
Ribi K, Marti WR, Bernhard J, Grieder F, Graf M, Gloor B, Curti G, Zuber M, Demartines N, Andrieu C, Bigler M, Hayoz S, Wehrli H, Kettelhack C, Lerf B, Fasolini F, Hamel CImpact-Faktor
3.93Typ
Swiss Cancer Institute trialsJournal
THER ADV MED ONCOLJahr
2019Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 44/00Title
Predicting mortality and adverse events in patients with advanced pancreatic cancer (APC) treated with palliative Gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scoresAutoren
Gargiulo P, Dietrich D, Herrmann R, Bodoky G, Ruhstaller T, Scheithauer W, Glimelius B, Berardi S, Pignata S, Brauchli PImpact-Faktor
0.955Typ
Swiss Cancer Institute trialsJournal
INVEST NEW DRUGSJahr
2019Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 67/15Title
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.Autoren
Joerger M, Stathis A, Metaxas Y, Hess D, Mantiero M, Mark M, Volden M, Kaindl T, Engelhardt M, Larger P, Lane H, Hafner P, Levy N, Stuedeli S, Sessa C, von Moos R.Impact-Faktor
2.919Typ
Swiss Cancer Institute trialsJournal
RADIAT ONCOLJahr
2019Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 75/08Title
Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer. A SAKK 75/08 SubstudyAutoren
Panje CM, Höng L, Hayoz S, Baracos VE, Herrmann E, Garcia Schüler H, Meier UR, Henke G, Schacher S, Hawle H, Gérard MA, Ruhstaller T, Plasswilm LImpact-Faktor
2.546Typ
Swiss Cancer Institute trialsJournal
J BONE ONCOLJahr
2019Krankheitsgruppe
Supportive CareStudie
SAKK 95/16Title
Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)Autoren
Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos RImpact-Faktor
2.886Typ
Swiss Cancer Institute servicesJournal
J UROLOGYJahr
2019Krankheitsgruppe
Urogenital CancersStudie
-Title
Characteristics and treatment outcomes of 1,375 localized and metastatic testicular Leydig cell tumors: a systematic literature review and meta-analysisAutoren
Fankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann KP, Sulser T, Bode PK, Clarke NW, Beyer J, Hermanns T.Impact-Faktor
5.647Typ
Swiss Cancer Institute servicesJournal
CLIN GENITOURIN CANCERJahr
2019Krankheitsgruppe
Urogenital CancersStudie
-Title
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.Autoren
Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R.Impact-Faktor
2.45Typ
Swiss Cancer Institute servicesJournal
LUNG CANCERJahr
2019Krankheitsgruppe
Lung CancersStudie
-Title
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort studyAutoren
Schmid S, Klingbiel D, Aeppli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh MImpact-Faktor
3.958Typ
Swiss Cancer Institute servicesJournal
BMC UROLJahr
2019Krankheitsgruppe
Radio-OncologyStudie
-Title
Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experienceAutoren
Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR.Impact-Faktor
1.792Typ
Swiss Cancer Institute servicesJournal
ANN SURG ONCOLJahr
2019Krankheitsgruppe
Breast CancersStudie
-Title
Prospective Evaluation of Residual Breast Tissue after SKIn- or NIpple-Sparing Mastectomy – Results of the SKINI-TrialAutoren
Papassotiropoulos B, Güth U, Chiesa F, Rageth C, Amann E, Baege A, Elfgen C, Varga Z, Moskovszky L, Endhardt K, Masser R, Tinguely M, Farhadi J, Lardi A, Dammann F, Diebold J, Li Q, Dubsky P, Tausch CImpact-Faktor
3.93Typ
Swiss Cancer Institute servicesJournal
ONCOL RES TREATJahr
2019Krankheitsgruppe
Urogenital CancersStudie
-Title
Shared decision making for patients with advanced urological malignancies – Evaluation of a joint urological-oncological clinic modelAutoren
Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C, Gillessen S, Engeler DS, Klingbiel D, Schmid HP, Omlin AImpact-Faktor
1.09Typ
OtherJournal
FRONT ONCOLJahr
2019Krankheitsgruppe
Cancers of Head and NeckStudie
-Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery).Autoren
Dulguerov P, Broglie MA, Henke G, Siano M, Putora PM, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Elicin O.Impact-Faktor
4.25Typ
OtherJournal
FRONT ONCOLJahr
2019Krankheitsgruppe
Cancers of Head and NeckStudie
-Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology).Autoren
Elicin O, Putora PM, Siano M, Broglie MA, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Dulguerov P, Henke G.Impact-Faktor
4.25Typ
OtherJournal
FRONT ONCOLJahr
2019Krankheitsgruppe
Cancers of Head and NeckStudie
-Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology).Autoren
Siano M, Dulguerov P, Broglie MA, Henke G, Putora PM, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Elicin O.Impact-Faktor
4.25Typ
OtherJournal
FRONT ONCOLJahr
2019Krankheitsgruppe
Cancers of Head and NeckStudie
-Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers).Autoren
Broglie MA, Dulguerov P, Henke G, Siano M, Putora PM, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Elicin O.Impact-Faktor
4.25Typ
Collaborative group trialsJournal
BR J CANCERJahr
2019Krankheitsgruppe
Breast CancersStudie
EORTC 10994Title
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.Autoren
Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron DImpact-Faktor
5.791Typ
Collaborative group trialsJournal
J THORAC ONCOLJahr
2019Krankheitsgruppe
Lung CancersStudie
ETOP BELIEFTitle
Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.Autoren
Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Fontecedro AC, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell RImpact-Faktor
5.282Typ
Collaborative group trialsJournal
BLOOD ADVJahr
2019Krankheitsgruppe
LeukemiasStudie
GRAALL 2003, GRAALL 2005Title
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.Autoren
Alcantara M, Simonin M, Lhermitte L, Touzart A, Dourthe ME, Latiri M, Grardel N, Cayuela JM, Chalandon Y, Graux C, Dombret H, Ifrah N, Petit A, Macintyre E, Baruchel A, Boissel N, Asnafi VImpact-Faktor
-Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2019Krankheitsgruppe
LymphomasStudie
HD 16Title
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupAutoren
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A.Impact-Faktor
18.428Typ
Collaborative group trialsJournal
BREAST CANCER RESJahr
2019Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98Autoren
Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RMImpact-Faktor
3.471Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2019Krankheitsgruppe
Breast CancersStudie
IBCSG 22-00Title
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.Autoren
Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels SImpact-Faktor
18.428Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2019Krankheitsgruppe
Breast CancersStudie
IBCSG 24-02, IBCSG 25-02Title
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFTAutoren
Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MMImpact-Faktor
26.303Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2019Krankheitsgruppe
Breast CancersStudie
IBCSG 24-02, IBCSG 25-02Title
Adjuvant systemic treatment of premenopausal women with hormone receptor–positive early breast cancer: Lights and shadows.Autoren
Regan MM, Fleming GF, Walley B, Francis PA, Pagani OImpact-Faktor
18.428Typ
Collaborative group trialsJournal
BR J CANCERJahr
2019Krankheitsgruppe
Breast CancersStudie
IBCSG 35-07Title
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.Autoren
Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard JImpact-Faktor
5.922Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2019Krankheitsgruppe
Breast CancersStudie
IBCSG VIII, IBCSG IX, IBCSG 18-98Title
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.Autoren
Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G.Impact-Faktor
3.94Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2019Krankheitsgruppe
LymphomasStudie
REMoDL-BTitle
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.Autoren
Davies AJ, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWMImpact-Faktor
24.69Typ
Collaborative group trialsJournal
EUR UROLJahr
2019Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAutoren
Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NWImpact-Faktor
13.938Typ
Swiss Cancer Institute trialsJournal
J THORAC ONCOLJahr
2018Krankheitsgruppe
Lung CancersStudie
SAKK 16/96, SAKK 16/00, SAKK 16/01Title
Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer: A Pooled Analysis on Long Term Results of three SAKK trials (SAKK 16/96, 16/00, 16/01)Autoren
Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein A, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless MImpact-Faktor
10.337Typ
Swiss Cancer Institute trialsJournal
ANN SURG ONCOLJahr
2018Krankheitsgruppe
Breast CancersStudie
SAKK 23/13Title
Impact of a Surgical Sealing Patch on Lymphatic Drainage after Axillary Dissection for Breast Cancer. The SAKK 23/13 Multicenter Randomized Phase III TrialAutoren
Weber WP, Tausch C, Hayoz S, Fehr MK, Ribi K, Hawle H, Lupatsch JE, Matter-Walstra K, Chiesa F, Dedes KJ, Berclaz G, Lelièvre L, Hess T, Güth U, Pioch V, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal SD, Ruhstaller T, Fehr PM, Knauer MImpact-Faktor
4.041Typ
Swiss Cancer Institute trialsJournal
TRIALSJahr
2018Krankheitsgruppe
Breast CancersStudie
SAKK 23/16Title
Tailored AXIllary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter randomized phase III trial.Autoren
Henke G, Knauer M, Ribi K, Hayoz S, Gérard MA, Ruhstaller T, Zwahlen DR, Muenst S, Ackerknecht M, Hawle H, Fitzal F, Gnant M, Mátrai Z, Ballardini B, Gyr A, Kurzeder C, Weber WP.Impact-Faktor
1.969Typ
Swiss Cancer Institute trialsJournal
HAEMATOLOGICAJahr
2018Krankheitsgruppe
LeukemiasStudie
SAKK 33/14Title
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14Autoren
Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides APA, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RCImpact-Faktor
5.814Typ
Swiss Cancer Institute trialsJournal
BLOODJahr
2018Krankheitsgruppe
LymphomasStudie
SAKK 39/13Title
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myelomaAutoren
Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander TImpact-Faktor
15.132Typ
Swiss Cancer Institute trialsJournal
ANN SURGJahr
2018Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 40/04Title
Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal Excision: A Swiss Prospective, Randomized, Multicenter Trial (SAKK 40/04)Autoren
Marti WR, Curti G, Wehrli H, Grieder F, Graf M, Gloor B, Zuber M, Demartines N, Fasolini F, Lerf B, Kettelhack C, Andrieu C, Bigler M, Hayoz S, Ribi K, Hamel CImpact-Faktor
8.569Typ
Swiss Cancer Institute trialsJournal
J GERIATR ONCOLJahr
2018Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 41/10Title
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in el-derly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10.Autoren
Kienle D, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder R C, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu A, von Moos RImpact-Faktor
3.359Typ
Swiss Cancer Institute trialsJournal
CANCERJahr
2018Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 56/07Title
Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumor: A Multicenter, 2-Stage Phase 2 Trial (Swiss Group for Clinical Cancer Research 56/07)Autoren
Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwarb H, Le Cesne A, Koeberle D, Bärtschi D, Dietrich D, Biaggi C, Prior J, Leyvraz SImpact-Faktor
6.537Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2018Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 67/13Title
First in Human, Phase 1, Dose Escalation Pharmacokinetic and Pharmacodynamic Study of the Oral Dual PI3K and mTORC1/2 Inhibitor PQR309 in Patients with Advanced Solid Tumors (SAKK 67/13)Autoren
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanovic N, Cmiljanovic V, Stumm M, Dimitrijevic S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit RImpact-Faktor
5.417Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2018Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 75/08Title
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)Autoren
Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, Plasswilm L, Budach W, Eisterer W, Hawle H, Mariette C, Hess V, Mingrone W, Montemurro M, Girschikofsky M, Schmidt SC, Bitzer M, Bedenne L, Brauchli P, Stahl MImpact-Faktor
11.855Typ
Swiss Cancer Institute servicesJournal
BREAST CANCERJahr
2018Krankheitsgruppe
Breast CancersStudie
-Title
Atypical ductal hyperplasia (ADH) and risk of underestimation: Method of tissue sampling, multicentricity and associated calcifications significantly influence upgrade rate in subsequent surgical specimensAutoren
Rageth CJ, Rubenov R, Bronz C, Dietrich D, Tausch C, Rodewald AK, Varga ZImpact-Faktor
1.772Typ
Swiss Cancer Institute servicesJournal
J THORAC ONCOLJahr
2018Krankheitsgruppe
Lung CancersStudie
-Title
Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma.Autoren
Metaxas I, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild S, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, John T.Impact-Faktor
5.282Typ
Swiss Cancer Institute servicesJournal
CANCER IMMUNOL IMMUNJahr
2018Krankheitsgruppe
Lung CancersStudie
-Title
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)Autoren
Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M.Impact-Faktor
4.711Typ
Swiss Cancer Institute servicesJournal
J CLIN ONCOLJahr
2018Krankheitsgruppe
Urogenital CancersStudie
-Title
Questioning the value of FDG PET for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group registryAutoren
Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C, Haugnes HS, Hentrich M, Fankhauser C, Gillessen S, Beyer J.Impact-Faktor
18.428Typ
Swiss Cancer Institute servicesJournal
INT J COLORECTAL DISJahr
2018Krankheitsgruppe
SurgeryStudie
-Title
The Growing Discrepancy between Resident Training in Colon Surgery and Rising Numbers of General Surgery GraduatesAutoren
Käser SA, Rickenbacher A, Cabalzar-Wondberg D, Schneider M, Dietrich D, Misselwitz B, Clavien PA, Turina MImpact-Faktor
2.383Typ
Swiss Cancer Institute servicesJournal
SWISS MED WKLYJahr
2018Krankheitsgruppe
Breast CancersStudie
-Title
Vitamin D levels in Swiss breast cancer survivors.Autoren
Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B.Impact-Faktor
1.895Typ
OtherJournal
ANN ONCOLJahr
2018Krankheitsgruppe
Breast CancersStudie
-Title
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).Autoren
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.Impact-Faktor
7.04Typ
OtherJournal
RADIOTHER ONCOLJahr
2018Krankheitsgruppe
Lung CancersStudie
-Title
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).Autoren
Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK).Impact-Faktor
4.363Typ
OtherJournal
ONCOTARGETJahr
2018Krankheitsgruppe
Gastrointestinal CancersStudie
-Title
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.Autoren
Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M.Impact-Faktor
5.168Typ
OtherJournal
SWISS MED WKLYJahr
2018Krankheitsgruppe
LymphomasStudie
-Title
Diagnosis and treatment of follicular lymphoma: an update.Autoren
Bargetzi M, Baumann R, Cogliatti S, Dietrich PY, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T, Renner C.Impact-Faktor
1.895Typ
Collaborative group trialsJournal
HAEMATOLOGICAJahr
2018Krankheitsgruppe
LeukemiasStudie
APL 2006Title
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL groupAutoren
Adès L, Thomas X, Bresler AG, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux PImpact-Faktor
5.814Typ
Collaborative group trialsJournal
HAEMATOLOGICAJahr
2018Krankheitsgruppe
LeukemiasStudie
APL 2006Title
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).Autoren
Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux PImpact-Faktor
5.814Typ
Collaborative group trialsJournal
BREASTJahr
2018Krankheitsgruppe
Breast CancersStudie
BCY3/BCC 2017Title
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients.Autoren
Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, Paluch-Shimon S, Loibl S, Partridge AH, Demeestere I, Azim HA Jr, Peccatori FA.Impact-Faktor
2.381Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2018Krankheitsgruppe
LeukemiasStudie
CML-IVTitle
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.Autoren
Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M.Impact-Faktor
10.431Typ
Collaborative group trialsJournal
HAEMATOLOGICAJahr
2018Krankheitsgruppe
LeukemiasStudie
CML-IVTitle
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.Autoren
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.Impact-Faktor
5.814Typ
Collaborative group trialsJournal
CANCERJahr
2018Krankheitsgruppe
LymphomasStudie
EMN-02 Hovon 95Title
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisAutoren
Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva SImpact-Faktor
6.537Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2018Krankheitsgruppe
Breast CancersStudie
EORTC 10994Title
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial.Autoren
Aalders KC, Touati N, Tryfonidis K, Annonay M, Litiere S, Bergh J, Bodmer A, Cameron DA, Bonnefoi HR; EORTC 10994/BIG 1-00 Study Investigators.Impact-Faktor
3.94Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2018Krankheitsgruppe
LeukemiasStudie
GRAALL 2005Title
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.Autoren
Huguet-Rigal F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL).Impact-Faktor
18.428Typ
Collaborative group trialsJournal
BLOOD CANCER JJahr
2018Krankheitsgruppe
LeukemiasStudie
GRAALL 2005Title
Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trialAutoren
Paillassa J, Leguay T, Thomas X, Huguet F, Audrain M, Lheritier V, Vianey-Saban C, Acquaviva-Bourdain C, Pagan C, Dombret H, Ifrah N, Boissel N, Hunault-Berger MImpact-Faktor
8.125Typ
Collaborative group trialsJournal
BLOODJahr
2018Krankheitsgruppe
LeukemiasStudie
GRAALL 2003, GRAALL 2005Title
PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcomeAutoren
Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I, Thomas X, Graux C, Chalandon Y, Leguay T, Lengliné E, Konopacki J, Quentin S, Delabesse E, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Lhéritier V, Soulier J, Dombret H, Clappier EImpact-Faktor
10.452Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2018Krankheitsgruppe
LymphomasStudie
HD 16, HD 17, HD 18Title
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: Results from the German Hodgkin Study Group trials HD16, HD17, and HD18.Autoren
Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C.Impact-Faktor
7.04Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2018Krankheitsgruppe
LymphomasStudie
HD 9, HD 12Title
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.Autoren
von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.Impact-Faktor
10.698Typ
Collaborative group trialsJournal
J INTERN MEDJahr
2018Krankheitsgruppe
LeukemiasStudie
HOVONTitle
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.Autoren
Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKKImpact-Faktor
7.598Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2018Krankheitsgruppe
LeukemiasStudie
HOVON 102Title
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemiaAutoren
Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJImpact-Faktor
10.431Typ
Collaborative group trialsJournal
NEW ENGL J MEDJahr
2018Krankheitsgruppe
LeukemiasStudie
HOVON 42A, HOVON 92, HOVON 102Title
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.Autoren
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.Impact-Faktor
59.558Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 TrialAutoren
Ruhstaller Th, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study GroupImpact-Faktor
26.303Typ
Collaborative group trialsJournal
JAMA ONCOLJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical TrialAutoren
Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, JeBailey L, Dolan S, Hackl W, Thuerlimann B, Viale G, Colleoni M, Regan MM, Loi SImpact-Faktor
20.871Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5Autoren
Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick JImpact-Faktor
26.303Typ
Collaborative group trialsJournal
ONCOLOGISTJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast CancerAutoren
Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven PImpact-Faktor
5.306Typ
Collaborative group trialsJournal
INT J RADIAT ONCOL BIOL PHYSJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 20-98Title
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 TrialAutoren
Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PAImpact-Faktor
4.495Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 22-00Title
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.Autoren
Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M.Impact-Faktor
3.94Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 23-01Title
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trialAutoren
Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch AImpact-Faktor
24.69Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2018Krankheitsgruppe
Breast CancersStudie
IBCSG 27-02Title
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR TrialAutoren
Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Paterson AHG, Rimawi MF, Lang I, Baena-Canada JM, Thürlimann B, Mamounas EP, Geyer CE, Jr., Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi SImpact-Faktor
18.428Typ
Collaborative group trialsJournal
JAMA ONCOLJahr
2018Krankheitsgruppe
Gastrointestinal CancersStudie
PETACC-3 / SAKK 60/00Title
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.Autoren
Valérie C, Mahachie J, Mauer M, Buclin T, Van Cutsem E, Roth A, Wagner ADImpact-Faktor
20.871Typ
Collaborative group trialsJournal
EUR J CANCERJahr
2018Krankheitsgruppe
Gastrointestinal CancersStudie
PETACC-3 / SAKK 60/00Title
Clinical and pharmacogenetic determinants of FOLFIRI toxicity: results of the PETACC-3 trialAutoren
Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, Fiocca R, Delorenzi M, Bosman F, Roth ADImpact-Faktor
5.417Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2018Krankheitsgruppe
LymphomasStudie
REMoDL-BTitle
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyAutoren
Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, Kennedy H, Thompson JS, Uddin R, Worrillow L, Chalkley R, van Hoppe M, Ahmed S, Maishman T, Caddy J, Schuh A, Mamot C, Burton C, Tooze R, Davies A, Du MQ, Johnson PWM, Westhead DRImpact-Faktor
18.428Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2018Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.Autoren
Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND; STAMPEDE Investigators.Impact-Faktor
7.04Typ
Collaborative group trialsJournal
EUR UROL ONCOLJahr
2018Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessAutoren
Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MBK, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Corss WR, Dearnaley DP, Gale J, Gibbs J, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS; Srihari N, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJImpact-Faktor
8.208Typ
Collaborative group trialsJournal
LANCETJahr
2018Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Autoren
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MRImpact-Faktor
39.207Typ
Swiss Cancer Institute trialsJournal
RADIAT ONCOLJahr
2017Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomyAutoren
Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, Daniel R. Zwahlen, Jürgen Stein, Tobias Hölscher, Philipp Gut, Bülent Polat, Guido Hildebrandt, Arndt-Christian Müller, Martin P. Putora, Alexandros Papachristofilou, Corinne Schär, Alan Dal Pra, Christine Biaggi Rudolf, Peter Wust, Daniel M. Aebersold, George N. ThalmannImpact-Faktor
4.328Typ
Swiss Cancer Institute trialsJournal
J TRANSL MEDJahr
2017Krankheitsgruppe
Lung CancersStudie
SAKK 19/05Title
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.Autoren
Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M.Impact-Faktor
3.694Typ
Swiss Cancer Institute trialsJournal
ENDOCR CONNECTJahr
2017Krankheitsgruppe
Breast CancersStudie
SAKK 21/12Title
Phase I Clinical and Pharmacokinetic Evaluation of the Androgen Receptor Modulator CR1447 in Patients with Advanced Breast Cancer (SAKK 21/12)Autoren
M. Zweifel, B. Thürlimann, S. Riniker, P. Weder, R. von Moos, O. Pagani, M. Bigler, K. M. Rothgiesser, C. Pilop, H. Hawle, P. Brauchli, C. Tapia, W. Schoenfeld, C. SessaImpact-Faktor
-Typ
Swiss Cancer Institute trialsJournal
BMC CANCERJahr
2017Krankheitsgruppe
Breast CancersStudie
SAKK 26/10Title
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)Autoren
BC Pestalozzi, C Tausch, KJ Dedes, C Rochlitz, S Zimmermann, R von Moos, R Winterhalder, T Ruhstaller, A Mueller, K Buser, M Borner, U Novak, C Uhlmann Nussbaum, B Seifert, M Bigler, V Bize, S Berardi Vilei, C Rageth, S AebiImpact-Faktor
3.288Typ
Swiss Cancer Institute trialsJournal
J HEMATOL ONCOLJahr
2017Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohortAutoren
Juskevicius D, Jucker D., Klingbiel D., Mamot C., Dirnhofer S., Tzankov A.Impact-Faktor
6.263Typ
Swiss Cancer Institute trialsJournal
SUPPORT CARE CANCERJahr
2017Krankheitsgruppe
LymphomasStudie
SAKK 38/08Title
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphomaAutoren
Rondeau S., Hitz F., Mey U., Enoiu M., Pabst T., Stathis A., Fischer N., Clough-Gorr K.M.Impact-Faktor
2.535Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2017Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 41/08Title
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)Autoren
R. von Moos, D. Koeberle, S. Schacher, S. Hayoz, R.C. Winterhalder, A. Roth, G. Bodoky, P. Samaras, M.D. Berger, D. Rauch, P. Saletti, L. Plasswilm, D. Zwahlen, U.R. Meier, P. Yan, P. Izzo, D. Klingbiel, D. Bärtschi, K. ZauggImpact-Faktor
6.029Typ
Swiss Cancer Institute trialsJournal
INVEST NEW DRUGSJahr
2017Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 65/12Title
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.Autoren
Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa CImpact-Faktor
3.484Typ
Swiss Cancer Institute trialsJournal
ANN SURGJahr
2017Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 75/06Title
Recurrence Patterns and Long-Term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal CancerAutoren
Steffen T, Dietrich D, Schnider A, Kettelhack C, Huber O, Marti WR, Furrer M, Gloor B, Schiesser M, Thierstein S, Brauchli P, Ruhstaller TImpact-Faktor
-Typ
Swiss Cancer Institute trialsJournal
RADIAT ONCOLJahr
2017Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 77/07Title
External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26Autoren
Evelyn Herrmann, Diana Naehrig, Manfred Sassowsky, Martin Bigler, Jeroen Buijsen, Ilja Ciernik, Daniel Zwahlen, Alessandra Franzetti Pellanda, Andreas Meister, Peter Brauchli, Simona Berardi, Erika Kuettel, Jean-François Dufour, Daniel M. AebersoldImpact-Faktor
2.466Typ
Swiss Cancer Institute servicesJournal
GYNECOL ONCOLJahr
2017Krankheitsgruppe
Gynecological CancersStudie
-Title
Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis.Autoren
Datta NR, Stutz E, Liu M, Rogers S, Klingbiel D, Siebenhüner A, Singh S, Bodis SImpact-Faktor
4.198Typ
Swiss Cancer Institute servicesJournal
BONE MARROW TRANSPLJahr
2017Krankheitsgruppe
LymphomasStudie
-Title
NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.Autoren
Jeker B, Novak U, Mansouri Taleghani B, Baerlocher GM, Seipel K, Mueller BU, Bigler M, Betticher D, Luethi JM, Farese S, Ruefer A, Pabst T.Impact-Faktor
3.57Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2017Krankheitsgruppe
Breast CancersStudie
EORTC 10085Title
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.Autoren
Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH.Impact-Faktor
7.04Typ
Collaborative group trialsJournal
MOD PATHOLJahr
2017Krankheitsgruppe
Breast CancersStudie
EORTC 10085Title
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramAutoren
Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Dinjens WN, van Marion R, van Diest PJ, Martens JW, van Deurzen CHImpact-Faktor
6.655Typ
Collaborative group trialsJournal
EUR J CANCERJahr
2017Krankheitsgruppe
Breast CancersStudie
EORTC 10085Title
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramAutoren
Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHMImpact-Faktor
5.417Typ
Collaborative group trialsJournal
LANCET RESPIR MEDJahr
2017Krankheitsgruppe
Lung CancersStudie
ETOP BELIEFTitle
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialAutoren
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative groupImpact-Faktor
15.328Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2017Krankheitsgruppe
SarcomasStudie
GeDDiSTitle
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trialAutoren
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare SImpact-Faktor
36.418Typ
Collaborative group trialsJournal
LANCETJahr
2017Krankheitsgruppe
LymphomasStudie
HD 18Title
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.Autoren
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.Impact-Faktor
39.207Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2017Krankheitsgruppe
LymphomasStudie
HD 18Title
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupAutoren
Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert AImpact-Faktor
26.509Typ
Collaborative group trialsJournal
BLOODJahr
2017Krankheitsgruppe
LeukemiasStudie
HOVON 102Title
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.Autoren
Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJImpact-Faktor
8.125Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2017Krankheitsgruppe
Breast CancersStudie
IBCSG 16-98Title
Long-Term Follow-Up of the Intergroup Exemestane StudyAutoren
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning Pe, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RCImpact-Faktor
26.303Typ
Collaborative group trialsJournal
ACTA ONCOLJahr
2017Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosisAutoren
Weischenfeldt KLH, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen MB, Ejlertsen B, Lykkesfeldt AEImpact-Faktor
3.473Typ
Collaborative group trialsJournal
ACTA ONCOLJahr
2017Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancerAutoren
Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BBImpact-Faktor
3.473Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2017Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 StudyAutoren
Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, Regan MM, Thürlimann BImpact-Faktor
26.303Typ
Collaborative group trialsJournal
EUR J CANCERJahr
2017Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2Autoren
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW, Translational Aromatase Inhibitor Overview Group (Trans-AIOG)Impact-Faktor
7.191Typ
Collaborative group trialsJournal
JCO PRECIS ONCOLJahr
2017Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple CancersAutoren
Willis S, Sun Y, Abramovitz M, Fei T, Young B, Lin X, Ni M, Achua J, Regan MM, Gray KP, Gray R, Wang V, Long B, Kammler R, Sparano JA, Williams C, Goldstein LJ, Salgado R, Loi S, Pruneri G, Viale G, Brown M, Leyland-Jones BImpact-Faktor
-Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2017Krankheitsgruppe
Breast CancersStudie
IBCSG 35-07Title
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialAutoren
Colleoni M, Weixiu Luo, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Erika Hitre, Marie-Pascale Graas, Edda Simoncini, Claus Kamby, Alastair Thompson, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Christian Marth, Bettina Müller, Seamus O'Reilly, Vincenzo Di Lauro, Andrea Gombos, Thomas Ruhstaller, Harold Burstein, Karin Ribi, Jürg Bernhard, Giuseppe Viale, Rudolf Maibach, Manuela Rabaglio-Poretti, Richard D Gelber, Alan S Coates, Angelo Di Leo, Meredith M Regan, Aron GoldhirschImpact-Faktor
24.69Typ
Collaborative group trialsJournal
NEW ENGL J MEDJahr
2017Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.Autoren
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MRImpact-Faktor
79.285Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2017Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.Autoren
Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AW, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, Ibrahim A, Logue J, Lydon A, Nikapota AD, O'Sullivan JM, Porfiri E, Protheroe A, Srihari NN, Tsang D, Wagstaff J, Wallace J, Walmsley C, Parmar MK, Sydes MR; STAMPEDE Investigators..Impact-Faktor
26.303Typ
Swiss Cancer Institute trialsJournal
PROSTATEJahr
2016Krankheitsgruppe
Urogenital CancersStudie
SAKK 08/11Title
Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: A multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11)Autoren
Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei SB, Rauch D, Roggero E, Mohaupt MG, Bernhard J, Manetsch G, Gillessen SImpact-Faktor
3.778Typ
Swiss Cancer Institute trialsJournal
BJU INTJahr
2016Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.Autoren
Ghadjar P, Hayoz S, Genitsch V, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Putora MP, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Khanfir K, Budach V, Aebersold DM, Thalmann GNImpact-Faktor
4.439Typ
Swiss Cancer Institute trialsJournal
STRAHLENTHER ONKOLJahr
2016Krankheitsgruppe
Cancers of Head and NeckStudie
SAKK 10/94Title
Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94)Autoren
Ghadjar P, Pöttgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F, Kaul D, Plasswilm L, Olze H, Bernier J, Wust P, Aebersold DM, Budach V.Impact-Faktor
2.914Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2016Krankheitsgruppe
Lung CancersStudie
SAKK 16/01Title
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.Autoren
Früh M, Ris H.B. , Xyrafas A. , Peters S. , Mirimanoff RO. , Gautschi O. , Pless M. , Stupp R.Impact-Faktor
7.04Typ
Swiss Cancer Institute trialsJournal
CLIN LUNG CANCERJahr
2016Krankheitsgruppe
Lung CancersStudie
SAKK 19/09Title
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous NoneSmall-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialAutoren
Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AFImpact-Faktor
3.104Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2016Krankheitsgruppe
Breast CancersStudie
SAKK 22/99Title
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99Autoren
Pagani O, Klingbiel D, Ruh-staller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos RV, Zaman K, Goldhirsch A; Swiss Group for ClinicalImpact-Faktor
7.04Typ
Swiss Cancer Institute trialsJournal
BMC CANCERJahr
2016Krankheitsgruppe
Breast CancersStudie
SAKK 24/09Title
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. Bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialAutoren
Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Kyung-Jae N, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder RImpact-Faktor
3.288Typ
Swiss Cancer Institute trialsJournal
HEMATOL ONCOLJahr
2016Krankheitsgruppe
LymphomasStudie
SAKK 37/05Title
Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).Autoren
Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M.Impact-Faktor
3.084Typ
Swiss Cancer Institute trialsJournal
BRIT J HAEMATOLJahr
2016Krankheitsgruppe
LymphomasStudie
SAKK 38/08Title
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy – SAKK 38/08Autoren
Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar CB, Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K, Berardi Vilei S, Rondeau S, Mey U.Impact-Faktor
4.71Typ
Swiss Cancer Institute trialsJournal
INT J COLORECTAL DISJahr
2016Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 40/00Title
Prospective multicenter registration study of colorectal cancer: significant variations in radicality and oncosurgical quality-Swiss Group for Clinical Cancer Research Protocol SAKK 40/00.Autoren
Maurer CA, Dietrich D, Schilling MK, Metzger U, Laffer U, Buchmann P, Lerf B, Villiger P, Melcher G, Klaiber C, Bilat C, Brauchli P, Terracciano L, Kessler K.Impact-Faktor
2.383Typ
Swiss Cancer Institute trialsJournal
CLIN COLORECTAL CANCJahr
2016Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 41/06Title
Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).Autoren
Matter-Walstra K, Schwenkglenks M, Betticher D, von Moos R, Dietrich D, Baertschi D, Koeberle D.Impact-Faktor
2.81Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2016Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 77/08Title
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)Autoren
J.-F. Dufour, G. Demeter, Q. Li, K. Ribi, P. Samaras, P. Saletti, A. D. Roth, D. Horber, M. Buehlmann, A. D. Wagner, M. Montemurro, G. Lakatos, J. Feilchenfeldt, M. Peck-Radosavljevic, D. Rauch, B. Tschanz, G. BodokyImpact-Faktor
9.269Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2016Krankheitsgruppe
Supportive CareStudie
SAKK 95/06Title
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)Autoren
Strasser F, Blum D, von Moos R, Cathomas R, Ribi K, Aebi S, Betticher D, Hayoz S, Klingbiel D, Brauchli P, Haefner M, Mauri S, Kaasa S, Koeberle DImpact-Faktor
7.04Typ
Swiss Cancer Institute servicesJournal
J BIOMED MATER RES AJahr
2016Krankheitsgruppe
-Studie
-Title
A systematic review and meta-analysis on the influence of biological implant surface coatings on periimplant bone formation.Autoren
Jenny G, Jauernik J, Bierbaum S, Bigler M, Grätz KW, Rücker M, Stadlinger B.Impact-Faktor
3.076Typ
Swiss Cancer Institute servicesJournal
J THORAC ONCOLJahr
2016Krankheitsgruppe
Lung CancersStudie
-Title
Clinical Outcome of ALK -Positive Non-Small Cell Lung Cancer (NSCLC) Patients with de novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKI).Autoren
Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh MImpact-Faktor
5.282Typ
Swiss Cancer Institute servicesJournal
INT J HYPERTHERJahr
2016Krankheitsgruppe
Urogenital CancersStudie
-Title
Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: A systematic review with conventional and network meta-analyses.Autoren
Rogers S, Klingbiel D, Gómez S, Puric E, Bodis S.Impact-Faktor
2.65Typ
Swiss Cancer Institute servicesJournal
J CLIN ONCOLJahr
2016Krankheitsgruppe
Urogenital CancersStudie
-Title
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I SeminomaAutoren
Fischer S., Tandstad T., Wheater M., Porfiri E., Fléchon A., Aparicio J., Klingbiel D., Skrbinc B., Basso U., Shamash J., Lorch A., Dieckmann KP, Cohn-Cedermark G., Ståhl O, Chau C., Arriola E., Marti K., Hutton P., Laguerre B., Maroto P., Beyer J., Gillessen S.Impact-Faktor
18.428Typ
OtherJournal
J THORAC ONCOLJahr
2016Krankheitsgruppe
Lung CancersStudie
-Title
A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing.Autoren
Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; SAKKImpact-Faktor
5.28Typ
OtherJournal
BREAST CANCER RES TRJahr
2016Krankheitsgruppe
Breast CancersStudie
-Title
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).Autoren
Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.Impact-Faktor
3.94Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2016Krankheitsgruppe
LeukemiasStudie
CLL 10Title
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority Trial.Autoren
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek MImpact-Faktor
24.69Typ
Collaborative group trialsJournal
EUR J CANCERJahr
2016Krankheitsgruppe
MelanomasStudie
EORTC 18952Title
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.Autoren
Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.Impact-Faktor
5.417Typ
Collaborative group trialsJournal
J THORAC ONCOLJahr
2016Krankheitsgruppe
Lung CancersStudie
ETOP EMPHASISTitle
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialAutoren
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EFImpact-Faktor
5.282Typ
Collaborative group trialsJournal
BLOODJahr
2016Krankheitsgruppe
LeukemiasStudie
HOVON 42, HOVON 43, HOVON 81, HOVON 92Title
Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemiaAutoren
Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, Löwenberg B, Leebeek FWG.Impact-Faktor
13.164Typ
Collaborative group trialsJournal
JAMA ONCOLJahr
2016Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer RecurrenceAutoren
Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, DellÔrto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou CImpact-Faktor
-Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2016Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in SequenceAutoren
Chrigwin J, Gibbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Láng I, Colleoni M, Thürlimann BImpact-Faktor
24.008Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2016Krankheitsgruppe
Breast CancersStudie
IBCSG 22-00Title
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.Autoren
Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A.Impact-Faktor
24.008Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2016Krankheitsgruppe
Breast CancersStudie
IBCSG 22-00Title
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Autoren
Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.Impact-Faktor
3.94Typ
Collaborative group trialsJournal
BR J CANCERJahr
2016Krankheitsgruppe
Breast CancersStudie
IBCSG 24-02Title
Adjuvant ovarian function suppression and cognitive function in women with breast cancerAutoren
Regan MM, Ribi K Francis PA Puglisi F Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard JImpact-Faktor
6.176Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2016Krankheitsgruppe
Breast CancersStudie
IBCSG 25-02Title
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT Trial.Autoren
Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA.Impact-Faktor
3.94Typ
Collaborative group trialsJournal
INT J RADIAT ONCOL BIOL PHYSJahr
2016Krankheitsgruppe
Breast CancersStudie
IBCSG VI, IBCSG VIITitle
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VIIAutoren
Karlsson P, Cole BF, Price KN, Gelber RD, Coates AS, Goldhirsch A, Castiglione M, Colleoni M, Gruber GImpact-Faktor
5.133Typ
Collaborative group trialsJournal
LANCETJahr
2016Krankheitsgruppe
Breast CancersStudie
IBIS-IITitle
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.Autoren
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.Impact-Faktor
39.207Typ
Collaborative group trialsJournal
LANCET HAEMATOLJahr
2016Krankheitsgruppe
LymphomasStudie
IELSG-32Title
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the fi rst randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAutoren
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus GImpact-Faktor
7.123Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2016Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialAutoren
Nicholas D James, Matthew R Sydes, Malcolm D Mason, Noel W Clarke, John Anderson, David P Dearnaley, John Dwyer, Gordana Jovic, Alastair W S Ritchie, J Martin Russell, Karen Sanders, George N Thalmann, Gian?lippo Bertelli, Alison J Birtle, Joe M O’Sullivan, Andrew Protheroe, Denise Sheehan, Narayanan Srihari, Mahesh K B Parmar, for the STAMPEDE investigatorsImpact-Faktor
33.9Typ
Collaborative group trialsJournal
HEMATOL ONCOLJahr
2016Krankheitsgruppe
LymphomasStudie
T-Cell ProjectTitle
Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative studyAutoren
Bellei M, Sabattini E, Pesce EA, Ko YH, Kim WS, Cabrera ME, Martinez V, Dlouhy I, Paes RP, Barrese T, Vassallo J, Tarantino V, Vose J, Weisenburger D, Rüdiger T, Federico M, Pileri SImpact-Faktor
3.118Typ
Swiss Cancer Institute trialsJournal
PROSTATE CANCER P DJahr
2015Krankheitsgruppe
Urogenital CancersStudie
SAKK 08/09Title
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)Autoren
M Joerger, Van Schaik, R.H.N., Becker, M.L., Hayoz, S., Pollak, M., Cathomas, R., Winterhalder, R., Gillessen, S., Rothermundt, C.Impact-Faktor
3.425Typ
Swiss Cancer Institute trialsJournal
J CLIN ONCOLJahr
2015Krankheitsgruppe
Urogenital CancersStudie
SAKK 09/10Title
Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.Autoren
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Kaouthar K, Wust P, Thalmann GN, Aebersold DM.Impact-Faktor
18.428Typ
Swiss Cancer Institute trialsJournal
RADIAT ONCOLJahr
2015Krankheitsgruppe
Cancers of Head and NeckStudie
SAKK 10/94Title
Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94)Autoren
Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, Bernier J, Studer G, Plasswilm L, Budach V, Aebersold DMImpact-Faktor
2.546Typ
Swiss Cancer Institute trialsJournal
LANCETJahr
2015Krankheitsgruppe
Lung CancersStudie
SAKK 16/00Title
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialAutoren
Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters SImpact-Faktor
44.002Typ
Swiss Cancer Institute trialsJournal
LANCET ONCOLJahr
2015Krankheitsgruppe
Lung CancersStudie
SAKK 17/04Title
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 Trial.Autoren
Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder WImpact-Faktor
24.69Typ
Swiss Cancer Institute trialsJournal
LUNG CANCERJahr
2015Krankheitsgruppe
Lung CancersStudie
SAKK 17/04Title
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.Autoren
Rusch A, Ziltener G, Nackaerts K, Weder W, Stahel RA, Felley-Bosco E.Impact-Faktor
3.958Typ
Swiss Cancer Institute trialsJournal
CLIN CANCER RESJahr
2015Krankheitsgruppe
Lung CancersStudie
SAKK 19/05Title
Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial).Autoren
Franzini A, Baty F, Macovei II, Dürr O, Droege C, Betticher D, Grigoriu BD, Klingbiel D, Zappa F, Brutsche MHImpact-Faktor
8.722Typ
Swiss Cancer Institute trialsJournal
CLIN LUNG CANCERJahr
2015Krankheitsgruppe
Lung CancersStudie
SAKK 19/09Title
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced NoneSmall-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Autoren
Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AFImpact-Faktor
3.104Typ
Swiss Cancer Institute trialsJournal
EUR J CANCERJahr
2015Krankheitsgruppe
Breast CancersStudie
SAKK 21/08Title
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.Autoren
Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P.Impact-Faktor
5.417Typ
Swiss Cancer Institute trialsJournal
PLOS ONEJahr
2015Krankheitsgruppe
Breast CancersStudie
SAKK 28/12Title
Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 StudyAutoren
Zsuzsanna Varga, Estelle Cassoly, Qiyu Li, Christian Oehlschlegel, Coya Tapia, Hans Anton Lehr, Dirk Klingbiel, Beat Thürlimann, Thomas RuhstallerImpact-Faktor
3.23Typ
Swiss Cancer Institute trialsJournal
J CLIN ONCOLJahr
2015Krankheitsgruppe
LymphomasStudie
SAKK 35/03Title
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.Autoren
Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini MImpact-Faktor
18.428Typ
Swiss Cancer Institute trialsJournal
J CLIN ONCOLJahr
2015Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).Autoren
Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.Impact-Faktor
18.428Typ
Swiss Cancer Institute trialsJournal
J HEMATOL ONCOLJahr
2015Krankheitsgruppe
LymphomasStudie
SAKK 38/07Title
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Autoren
Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S.Impact-Faktor
4.812Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2015Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 41/06Title
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).Autoren
Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Frueh M, Kueng M, Popescu RA, Schacher S, Hess V, Herrmann R.Impact-Faktor
9.269Typ
Swiss Cancer Institute trialsJournal
ANN ONCOLJahr
2015Krankheitsgruppe
Gastrointestinal CancersStudie
SAKK 43/99Title
Pre-operative versus post-operative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.Autoren
Fazio N, Biffi R, Maibach R, Hayoz S, Thierstein S, Brauchli P, Bernhard J, Stupp R, Andreoni B, Renne G, Crosta C, Morant R, Chiappa A, Luca F, Zampino MG, Huber O11, Goldhirsch A, de Braud F, Roth ADImpact-Faktor
7.04Typ
Swiss Cancer Institute trialsJournal
HAEMATOLOGICAJahr
2015Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 65/08Title
Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).Autoren
Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJImpact-Faktor
5.814Typ
Swiss Cancer Institute servicesJournal
INT J RADIAT ONCOL BIOL PHYSJahr
2015Krankheitsgruppe
Breast CancersStudie
-Title
Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysisAutoren
Puric E, Klingbiel D, Gomez S, Bodis S.Impact-Faktor
4.258Typ
Swiss Cancer Institute servicesJournal
RADIAT ONCOLJahr
2015Krankheitsgruppe
Urogenital CancersStudie
-Title
Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.Autoren
Zips D, Heinrich V, Lamprecht U, Voigt O, Burock S, Budach V, Wust P, Ghadjar P.Impact-Faktor
2.546Typ
Swiss Cancer Institute servicesJournal
ANN ONCOLJahr
2015Krankheitsgruppe
Urogenital CancersStudie
-Title
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ cell tumour: Results from a 17 year UK experience.Autoren
Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T.Impact-Faktor
7.04Typ
Swiss Cancer Institute servicesJournal
SUPPORT CARE CANCERJahr
2015Krankheitsgruppe
Lung CancersStudie
-Title
Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.Autoren
Volk V, Cathomas R, Mark M, von Moos R, Klingbiel D, Brossart P, Mey U.Impact-Faktor
2.364Typ
OtherJournal
RADIAT ONCOLJahr
2015Krankheitsgruppe
Gastrointestinal CancersStudie
-Title
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland.Autoren
Putora PM, Bedenne L, Budach W, Eisterer W, Van Der Gaast A, Jäger R, Van Lanschot JJ, Mariette C, Schnider A, Stahl M, Ruhstaller T.Impact-Faktor
2.546Typ
Collaborative group trialsJournal
CANCERJahr
2015Krankheitsgruppe
LeukemiasStudie
APL 2006Title
Evolving Characteristics and Outcome of Secondary Acute Promyelocytic Leukemia (APL): A Prospective Analysis by the French-Belgian-Swiss APL GroupAutoren
Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL GroupImpact-Faktor
5.649Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2015Krankheitsgruppe
LeukemiasStudie
APL PROMYSE RegTitle
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.Autoren
Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia M, Huerta AJ, Nloga AM, González-Sanmiguel JD, Schmidt A, Lambert JF, Lehmann S, Di Bona E, Cassinat B, Hofmann WK, Görlich D, Sauerland MC, Fenaux P, Sanz MImpact-Faktor
12.104Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2015Krankheitsgruppe
Gastrointestinal CancersStudie
CAPP2Title
Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.Autoren
Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC.Impact-Faktor
20.982Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2015Krankheitsgruppe
LeukemiasStudie
CML IIIATitle
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatmentAutoren
Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baumann H, Kuse R, Schmitz N, Wehmeier A, Fischer JTH, Ho AD, Wilhelm M, Goebeler M-E, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kold H-J, Büusche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R for the SAKK and the German CML Study GroupImpact-Faktor
12.104Typ
Collaborative group trialsJournal
LANCETJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsAutoren
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Impact-Faktor
44.002Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialAutoren
Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MMImpact-Faktor
4.085Typ
Collaborative group trialsJournal
BREAST CANCER RES TRJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerAutoren
Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price KN, Coates AS, Goldhirsch A, Gelber RD, Pagani O, Viale G, Rae JM, Regan MM, in behalf of the BIG 1-98 Collaborative GroupImpact-Faktor
4.805Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialAutoren
Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M, International Breast Cancer Study Group and the BIG 1-98 Collaborative GroupImpact-Faktor
9.269Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 TrialAutoren
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch AImpact-Faktor
20.982Typ
Collaborative group trialsJournal
EUR J CANCERJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 20-98Title
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAutoren
Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown JImpact-Faktor
6.163Typ
Collaborative group trialsJournal
NEW ENGL J MEDJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 34-05Title
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.Autoren
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KSImpact-Faktor
55.873Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2015Krankheitsgruppe
Breast CancersStudie
IBCSG 36-07Title
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization TrialAutoren
Piccart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EAImpact-Faktor
18.443Typ
Collaborative group trialsJournal
LANCETJahr
2015Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Autoren
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.Impact-Faktor
44.002Typ
Collaborative group trialsJournal
JAMA ONCOLJahr
2015Krankheitsgruppe
Urogenital CancersStudie
STAMPEDETitle
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer Data From Patients in the Control Arm of the STAMPEDE TrialAutoren
James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD; Parker CC, Ritchie AWS, Russell JM, Schiavone F, Attard G, de Bono JS, Birtle A, Engeler DS, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MKB, Sydes MR for the STAMPEDE InvestigatorsImpact-Faktor
-Typ
Swiss Cancer Institute trialsJournal
NAT COMMUNJahr
2025Krankheitsgruppe
Lung CancersStudie
SAKK 16/14Title
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyAutoren
Schmid D, Sobottka B, Manzo M, Trüb M, Leonards K, Herzig P, Oyewole OR, Jermann P, Hayoz S, Savic Prince S, Tochtermann G, Natoli M, Pless M, Bettini A, Früh M, Mauti LA, Britschgi C, Peters S, Mark M, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Gonzalez M, Alborelli I, Rothschild SI, Koelzer VH, Zippelius AImpact-Faktor
15.7Typ
Swiss Cancer Institute trialsJournal
ONCOLOGYJahr
2025Krankheitsgruppe
Developmental TherapeuticsStudie
SAKK 80/19_AlpineTIRTitle
Unsupervised dynamic ePRO reporting of immunotherapy related symptoms in cancer patientsAutoren
Stauffacher AK, von Stockar L, Witschel HF, Hayoz S, Petrausch U, Schmid T, Jakob A, Kullak-Ublick GA, Trojan AImpact-Faktor
1.8Typ
Swiss Cancer Institute servicesJournal
CANCERSJahr
2025Krankheitsgruppe
LeukemiasStudie
-Title
Prognostic impact of the AML60+ score for elderly patients with acute myeloid leukemia treated with hypomethylating agents – a retrospective multicentric analysisAutoren
Petermilch V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede J, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle TImpact-Faktor
5.326Typ
Collaborative group trialsJournal
LANCET ONCOLJahr
2025Krankheitsgruppe
LymphomasStudie
HD 21Title
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialAutoren
Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Hellmuth JC, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Jablonski J, Damaschin C, Robertz AS, Rosenbrock J, Fuchs M, Borchmann P, Behringer KImpact-Faktor
35.9Typ
Collaborative group trialsJournal
LEUKEMIAJahr
2025Krankheitsgruppe
LeukemiasStudie
HOVON 132Title
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialAutoren
Mocking TR, Haaksma LH, Reuvekamp T, Kelder A, Scholten WJ, Ngai LL, Breems DA, Fischer T, Gjertsen BT, Griškevicius L, Juliusson G, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, van de Loosdrecht AA, Cloos J, Bachas CImpact-Faktor
12.8Typ
Collaborative group trialsJournal
JCO PRECIS ONCOLJahr
2025Krankheitsgruppe
Breast CancersStudie
IBCSG 18-98Title
Genomic characterization and prognostic significance of HER2-low, hormone receptor-positive, early breast cancers from the BIG 1-98 and SOFT clinical trialsAutoren
Luen SJ, Brown LC, van Geelen CT, Savas P, Kammler R, Dell’Orto P, Biasi O, Coates AS, Gelber RD, Thuerlimann B, Colleoni M, Fleming GF, Francis PA, Regan MM, Viale G, Loi SImpact-Faktor
5.6Typ
Collaborative group trialsJournal
CANCERJahr
2025Krankheitsgruppe
Breast CancersStudie
IBCSG 25-02Title
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTAutoren
Ribi K, Cole BF, Fleming GF, Walley BA, Francis PA, Abdi E, Burstein HJ, Cheng KL, Chia SKL, Dakhil SR, Davidson NE, Della-Fiorentina SA, Frith AE, Levine E, Lupichuk S, Pritchard K, Salim M, Stearns V, Stewart J, Valero V, van der Westhuizen A, Pagani O, Loi S, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard JImpact-Faktor
5.1Typ
Collaborative group trialsJournal
EUR J CANCERJahr
2025Krankheitsgruppe
Breast CancersStudie
IBCSG 35-07Title
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trialAutoren
Biganzoli G, Richard F, Isnaldi E, Marano G, Boracchi P, Maetens M, Floris G, Neven P, Jerusalem G, Munzone E, Hitre E, Gombos A, Thompson A, Aebi S, Kammler R, Dell’Orto P, Viale G, Regan MM, Colleoni M, Biganzoli E, Desmedt CImpact-Faktor
7.1Typ
Collaborative group trialsJournal
BREASTJahr
2025Krankheitsgruppe
Breast CancersStudie
IBCSG 48-14 POSITIVETitle
Breastfeeding after hormone receptor-positive breast cancer: Results from the Positive TrialAutoren
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA JrImpact-Faktor
7.9Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2025Krankheitsgruppe
Breast CancersStudie
IBCSG 48-14 POSITIVETitle
Breastfeeding after hormone receptor-positive breast cancer: Results from the Positive TrialAutoren
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA JrImpact-Faktor
42.1Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2025Krankheitsgruppe
Breast CancersStudie
IBCSG 55-17 TOUCHTitle
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)Autoren
Malorni L, Tyekucheva S, Gombos A, Hasler-Stub U, Zamgani C, Chakiba-Brugere, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Rueep B, Loi S, Viale G, Regan MM, Brain E, Biganzoli LImpact-Faktor
65.4Typ
Collaborative group trialsJournal
BLOODJahr
2024Krankheitsgruppe
LeukemiasStudie
GRAALL 2014Title
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemiaAutoren
Chalandon Y, Rousselot P, Chevret S, Cayuela JM, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie S, Thomas X, Vincent L, Berthon C, Hicheri Y, Raffoux E, Escoffre-Barbe M, Plantier I, Joris M, Turlure P, Pasquier F, Belhabri A, Guepin GR, Blum S, Gregor M, Lafage-Pochitaloff M, Quessada J, Lhéritier V, Clappier E, Boissel N, Dombret HImpact-Faktor
23.1Typ
Collaborative group trialsJournal
J CLIN ONCOLJahr
2024Krankheitsgruppe
LeukemiasStudie
GRAALL 2014Title
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 StudyAutoren
Kim R, Chalandon Y, Rousselot P, Cayuela JM, Huguet F, Balsat M, Passet M, Chevallier P, Hicheri Y, Raffoux E, Leguay T, Chantepie S, Maury S, Hayette S, Solly F, Braun T, De Prijck B, Cacheux V, Salanoubat C, Farnault L, Guibaud I, Lamarque M, Gastaud L, Lemasle E, Brissot E, Tavernier E, Bilger K, Villate A, Soulier J, Graux C, Lhéritier V, Dombret H, Boissel N, Clappier EImpact-Faktor
42.1Typ
Collaborative group trialsJournal
J IMMUNOTHER CANCERJahr
2023Krankheitsgruppe
Lung CancersStudie
ETOP PROMISE-mesoTitle
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.Autoren
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RAImpact-Faktor
10.9Typ
Collaborative group trialsJournal
LANCETJahr
2022Krankheitsgruppe
SarcomasStudie
EURO EWING 2012Title
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trialAutoren
Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J, Wheatley K.Impact-Faktor
18.97Typ
Collaborative group trialsJournal
ANN ONCOLJahr
2022Krankheitsgruppe
Breast CancersStudie
IBCSG 50-14 OLYMPIATitle
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerAutoren
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, SenkusImpact-Faktor
50.5Typ
Collaborative group trialsJournal
NEW ENGL J MEDJahr
2021Krankheitsgruppe
Breast CancersStudie
IBCSG 50-14 OLYMPIATitle
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast CancerAutoren
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE JrImpact-Faktor
176.079Keine Ergebnisse gefunden zu Ihrer Filterung